Epilepsy: Molecular Pathogenesis and Emerging Therapies

Abstract

Epilepsy is a prevalent and often severe neurological disorder with significant economic and societal impacts. Despite adequate trials with two or more antiseizure medications (ASMs), approximately one-third of patients continue to experience drug-resistant epilepsy. Surgery remains the most effective treatment for patients with drug-resistant focal epilepsy, yet it may be underutilized. Given the unsatisfactory clinical outcomes, it is imperative to investigate the molecular pathogenesis of epilepsy and to develop novel therapeutic strategies. This review systematically outlines the advances in understanding the etiology and molecular pathogenesis of epilepsy. These advances have identified diverse therapeutic targets, stimulating the development of emerging therapies, including novel ASM, minimally invasive surgery, neurostimulation, focused ultrasound, nanomedicine, gamma-aminobutyric acid (GABA)ergic cell therapy, and gene therapy. Additionally, the review comprehensively evaluates emerging therapies for epilepsy from different perspectives by integrating findings from both preclinical and clinical studies. These innovative approaches offer the potential for long-term seizure control. A great deal of future research is still needed to overcome current shortcomings. This work provides a cohesive framework that bridges molecular mechanisms with therapeutic applications. Such efforts may provide novel ideas and optimizing approaches in the field, ultimately advancing the precision and effectiveness of epilepsy treatments in the future.

Keywords

clinical trials / effect evaluation / emerging therapy / epilepsy / molecular pathogenesis / precision medicine

References

[1] O. Devinsky, A. Vezzani, T. J. O'Brien, et al., “Epilepsy,” Nature Reviews Disease Primers 4 (2018): 18024.

[2] R. N. Menon and J. Helen Cross, “Childhood Epilepsy,” Lancet 406, no. 10503 (2025): 636–649.

[3] GBD 2016 DALYs and HALE Collaborators, “Global, Regional, and National Disability-Adjusted Life-Years (DALYs) for 359 Diseases and Injuries and Healthy Life Expectancy (HALE) for 195 Countries and Territories, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017,” Lancet 392, no. 10159 (2018): 1859–1922.

[4] A. M. Kanner and M. M. Bicchi, “Antiseizure Medications for Adults With Epilepsy: A Review,” JAMA 327, no. 13 (2022): 1269–1281.

[5] T. Ravizza, M. Scheper, R. Di Sapia, J. Gorter, E. Aronica, and A. Vezzani, “mTOR and Neuroinflammation in Epilepsy: Implications for Disease Progression and Treatment,” Nature Reviews Neuroscience 25, no. 5 (2024): 334–350.

[6] I. E. Scheffer, S. Berkovic, G. Capovilla, et al., “ILAE Classification of the Epilepsies: Position Paper of the ILAE Commission for Classification and Terminology,” Epilepsia 58, no. 4 (2017): 512–521.

[7] S. Beniczky, E. Trinka, E. Wirrell, et al., “Updated Classification of Epileptic Seizures: Position Paper of the International League Against Epilepsy,” Epilepsia 66, no. 6 (2025): 1804–1823.

[8] D. Debanne, K. Mylonaki, M. L. Musella, and M. Russier, “Voltage-Gated Ion Channels in Epilepsies: Circuit Dysfunctions and Treatments,” Trends in Pharmacological Sciences 45, no. 11 (2024): 1018–1032.

[9] E. J. H. van van Hugte, D. Schubert, and N. Nadif Kasri, “Excitatory/Inhibitory Balance in Epilepsies and Neurodevelopmental Disorders: Depolarizing Gamma-Aminobutyric Acid as a Common Mechanism,” Epilepsia 64, no. 8 (2023): 1975–1990.

[10] C. Steriade, J. Bauer, and C. G. Bien, “Autoimmune Encephalitis-Associated Epilepsy,” Nature Reviews Neurology 21, no. 6 (2025): 312–326.

[11] A. Hollis and J. R. Lukens, “Role of Inflammasomes and Neuroinflammation in Epilepsy,” Immunological Reviews 329, no. 1 (2025): e13421.

[12] J. M. Rho and D. Boison, “The Metabolic Basis of Epilepsy,” Nature Reviews Neurology 18, no. 6 (2022): 333–347.

[13] N. Huang, Y. Huang, Z. Deng, et al., “Blood‑Brain Barrier Dysfunction in Epilepsy: Mechanisms, Therapeutic Strategies and Future Orientation (Review),” International Journal of Molecular Medicine 56, no. 3 (2025): 136.

[14] A. W. Pong, K. J. Xu, and P. Klein, “Recent Advances in Pharmacotherapy for Epilepsy,” Current Opinion in Neurology 36, no. 2 (2023): 77–85.

[15] P. Ryvlin, S. Rheims, L. J. Hirsch, A. Sokolov, and L. Jehi, “Neuromodulation in Epilepsy: State-of-the-Art Approved Therapies,” Lancet Neurology 20, no. 12 (2021): 1038–1047.

[16] J. A. Gonzalez-Martinez, “Epilepsy Surgery in the Last 10 Years: Advancements and Controversies,” Epilepsy Currents (2025): 15357597251344166.

[17] V. Krishna, F. Sammartino, and A. Rezai, “A Review of the Current Therapies, Challenges, and Future Directions of Transcranial Focused Ultrasound Technology: Advances in Diagnosis and Treatment,” JAMA Neurology 75, no. 2 (2018): 246–254.

[18] A. Movahedpour, R. Taghvaeefar, A. A. Asadi-Pooya, et al., “Nano-Delivery Systems as a Promising Therapeutic Potential for Epilepsy: Current Status and Future Perspectives,” CNS Neuroscience & Therapeutics 29, no. 11 (2023): 3150–3159.

[19] Z. Zhou, K. Li, Y. Guo, et al., “ROS/Electro Dual-Reactive Nanogel for Targeting Epileptic Foci to Remodel Aberrant Circuits and Inflammatory Microenvironment,” ACS Nano 17, no. 8 (2023): 7847–7864.

[20] S. Yang, E. Baeg, K. Kim, et al., “Neurodiagnostic and Neurotherapeutic Potential of Graphene Nanomaterials,” Biosensors & Bioelectronics 247 (2024): 115906.

[21] A. K. Shetty and D. Upadhya, “GABA-Ergic Cell Therapy for Epilepsy: Advances, Limitations and Challenges,” Neuroscience and Biobehavioral Reviews 62 (2016): 35–47.

[22] J. S. Street, Y. Qiu, and G. Lignani, “Are Genetic Therapies for Epilepsy Ready for the Clinic?,” Epilepsy Currents 23, no. 4 (2023): 245–250.

[23] R. Guerrini, S. Balestrini, E. C. Wirrell, and M. C. Walker, “Monogenic Epilepsies: Disease Mechanisms, Clinical Phenotypes, and Targeted Therapies,” Neurology 97, no. 17 (2021): 817–831.

[24] E. Akyuz, A. K. Polat, E. Eroglu, I. Kullu, E. Angelopoulou, and Y. N. Paudel, “Revisiting the Role of Neurotransmitters in Epilepsy: An Updated Review,” Life Sciences 265 (2021): 118826.

[25] A. Patel, Y. Meng, A. Najjar, F. Lado, and S. Najjar, “Autoimmune Encephalitis: A Physician's Guide to the Clinical Spectrum Diagnosis and Management,” Brain Sciences 12, no. 9 (2022): 1130.

[26] W. Li, J. Wu, Y. Zeng, and W. Zheng, “Neuroinflammation in Epileptogenesis: From Pathophysiology to Therapeutic Strategies,” Frontiers in Immunology 14 (2023): 1269241.

[27] R. Guerrini and W. B. Dobyns, “Malformations of Cortical Development: Clinical Features and Genetic Causes,” Lancet Neurology 13, no. 7 (2014): 710–726.

[28] A. McTague, K. B. Howell, J. H. Cross, M. A. Kurian, and I. E. Scheffer, “The Genetic Landscape of the Epileptic Encephalopathies of Infancy and Childhood,” Lancet Neurology 15, no. 3 (2016): 304–316.

[29] L. Claes, J. Del-Favero, B. Ceulemans, L. Lagae, C. Van Broeckhoven, and P. De Jonghe, “De Novo Mutations in the Sodium-Channel Gene SCN1A Cause Severe Myoclonic Epilepsy of Infancy,” American Journal of Human Genetics 68, no. 6 (2001): 1327–1332.

[30] S. Weckhuysen, S. Mandelstam, A. Suls, et al., “KCNQ2 Encephalopathy: Emerging Phenotype of a Neonatal Epileptic Encephalopathy,” Annals of Neurology 71, no. 1 (2012): 15–25.

[31] I. Helbig, H. C. Mefford, A. J. Sharp, et al., “15q13.3 Microdeletions Increase Risk of Idiopathic Generalized Epilepsy,” Nature Genetics 41, no. 2 (2009): 160–162.

[32] L. M. Dibbens, S. Mullen, I. Helbig, et al., “Familial and Sporadic 15q13.3 Microdeletions in Idiopathic Generalized Epilepsy: Precedent for Disorders With Complex Inheritance,” Human Molecular Genetics 18, no. 19 (2009): 3626–3631.

[33] C. Depienne, O. Trouillard, I. Gourfinkel-An, et al., “Mechanisms for Variable Expressivity of Inherited SCN1A Mutations Causing Dravet Syndrome,” Journal of Medical Genetics 47, no. 6 (2010): 404–410.

[34] A. Vezzani, R. S. Fujinami, H. S. White, et al., “Infections, Inflammation and Epilepsy,” Acta Neuropathologica 131, no. 2 (2016): 211–234.

[35] Y. N. Qiao, L. Li, S. H. Hu, et al., “Ketogenic Diet-Produced Beta-Hydroxybutyric Acid Accumulates Brain GABA and Increases GABA/Glutamate Ratio to Inhibit Epilepsy,” Cell Discovery 10, no. 1 (2024): 17.

[36] E. Lancaster and J. Dalmau, “Neuronal Autoantigens–Pathogenesis, Associated Disorders and Antibody Testing,” Nature Reviews Neurology 8, no. 7 (2012): 380–390.

[37] A. Mazarati and R. Sankar, “Common Mechanisms Underlying Epileptogenesis and the Comorbidities of Epilepsy,” Cold Spring Harbor Perspectives in Medicine 6, no. 7 (2016): a022798.

[38] Y. Yu, W. Li, and J. Jiang, “TRPC Channels as Emerging Targets for Seizure Disorders,” Trends in Pharmacological Sciences 43, no. 9 (2022): 787–798.

[39] Y. Cheng, W. Zhang, Y. Li, et al., “The Role of ASIC1a in Epilepsy: A Potential Therapeutic Target,” Current Neuropharmacology 19, no. 11 (2021): 1855–1864.

[40] G. P. Brennan, T. Z. Baram, and N. P. Poolos, “Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channels in Epilepsy,” Cold Spring Harbor Perspectives in Medicine 6, no. 3 (2016): a022384.

[41] P. Y. Maillard, S. Baer, E. Schaefer, et al., “Molecular and Clinical Descriptions of Patients With GABA(A) Receptor Gene Variants (GABRA1, GABRB2, GABRB3, GABRG2): A Cohort Study, Review of Literature, and Genotype-Phenotype Correlation,” Epilepsia 63, no. 10 (2022): 2519–2533.

[42] D. I. Kaplan, L. L. Isom, and S. Petrou, “Role of Sodium Channels in Epilepsy,” Cold Spring Harbor Perspectives in Medicine 6, no. 6 (2016): a022814.

[43] W. A. Catterall, “Sodium Channels, Inherited Epilepsy, and Antiepileptic Drugs,” Annual Review of Pharmacology and Toxicology 54 (2014): 317–338.

[44] R. Kohling and J. Wolfart, “Potassium Channels in Epilepsy,” Cold Spring Harbor Perspectives in Medicine 6, no. 5 (2016): a022871.

[45] B. A. Cole, S. J. Clapcote, S. P. Muench, and J. D. Lippiat, “Targeting K(Na)1.1 Channels in KCNT1-Associated Epilepsy,” Trends in Pharmacological Sciences 42, no. 8 (2021): 700–713.

[46] S. Rajakulendran and M. G. Hanna, “The Role of Calcium Channels in Epilepsy,” Cold Spring Harbor Perspectives in Medicine 6, no. 1 (2016): a022723.

[47] M. Jakimiec, J. Paprocka, and R. Smigiel, “CDKL5 Deficiency Disorder-A Complex Epileptic Encephalopathy,” Brain Sciences 10, no. 2 (2020): 107.

[48] J. Jiang and Y. Yu, “Pharmacologically Targeting Transient Receptor Potential Channels for Seizures and Epilepsy: Emerging Preclinical Evidence of Druggability,” Pharmacology & Therapeutics 244 (2023): 108384.

[49] F. Yang, X. Sun, Y. Ding, et al., “Astrocytic Acid-Sensing Ion Channel 1a Contributes to the Development of Chronic Epileptogenesis,” Scientific Reports 6 (2016): 31581.

[50] B. Santoro and M. M. Shah, “Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels as Drug Targets for Neurological Disorders,” Annual Review of Pharmacology and Toxicology 60 (2020): 109–131.

[51] J. Oyrer, S. Maljevic, I. E. Scheffer, S. F. Berkovic, S. Petrou, and C. A. Reid, “Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies,” Pharmacological Reviews 70, no. 1 (2018): 142–173.

[52] T. Sutula, G. Cascino, J. Cavazos, I. Parada, and L. Ramirez, “Mossy Fiber Synaptic Reorganization in the Epileptic Human Temporal Lobe,” Annals of Neurology 26, no. 3 (1989): 321–330.

[53] U. Haussler, K. Rinas, A. Kilias, U. Egert, and C. A. Haas, “Mossy Fiber Sprouting and Pyramidal Cell Dispersion in the Hippocampal CA2 Region in a Mouse Model of Temporal Lobe Epilepsy,” Hippocampus 26, no. 5 (2016): 577–588.

[54] X. Qian, J. Q. Ding, X. Zhao, et al., “Proteomic Analysis Reveals the Vital Role of Synaptic Plasticity in the Pathogenesis of Temporal Lobe Epilepsy,” Neural Plasticity 2022 (2022): 8511066.

[55] J. Albrecht and M. Zielinska, “Mechanisms of Excessive Extracellular Glutamate Accumulation in Temporal Lobe Epilepsy,” Neurochemical Research 42, no. 6 (2017): 1724–1734.

[56] E. Dossi and G. Huberfeld, “GABAergic Circuits Drive Focal Seizures,” Neurobiology of Disease 180 (2023): 106102.

[57] C. Neuray, R. Maroofian, M. Scala, et al., “Early-Infantile Onset Epilepsy and Developmental Delay Caused by Bi-Allelic GAD1 Variants,” Brain 143, no. 8 (2020): 2388–2397.

[58] H. Lee, E. H. Doud, R. Wu, et al., “Mechanism of Inactivation of Gamma-Aminobutyric Acid Aminotransferase by (1S,3S)-3-Amino-4-Difluoromethylene-1-Cyclopentanoic Acid (CPP-115),” Journal of the American Chemical Society 137, no. 7 (2015): 2628–2640.

[59] C. Geis, J. Planaguma, M. Carreno, F. Graus, and J. Dalmau, “Autoimmune Seizures and Epilepsy,” Journal of Clinical Investigation 129, no. 3 (2019): 926–940.

[60] A. Vezzani, S. Balosso, and T. Ravizza, “Neuroinflammatory Pathways as Treatment Targets and Biomarkers in Epilepsy,” Nature Reviews Neurology 15, no. 8 (2019): 459–472.

[61] A. Dey, X. Kang, J. Qiu, Y. Du, and J. Jiang, “Anti-Inflammatory Small Molecules to Treat Seizures and Epilepsy: From Bench to Bedside,” Trends in Pharmacological Sciences 37, no. 6 (2016): 463–484.

[62] G. A. Dienel, L. Gillinder, A. McGonigal, and K. Borges, “Potential New Roles for Glycogen in Epilepsy,” Epilepsia 64, no. 1 (2023): 29–53.

[63] W. H. Moos, D. V. Faller, I. P. Glavas, et al., “Epilepsy: Mitochondrial Connections to the ‘Sacred’ Disease,” Mitochondrion 72 (2023): 84–101.

[64] J. N. Pearson-Smith and M. Patel, “Metabolic Dysfunction and Oxidative Stress in Epilepsy,” International Journal of Molecular Sciences 18, no. 11 (2017): 2365.

[65] S. Sharma and A. N. Prasad, “Inborn Errors of Metabolism and Epilepsy: Current Understanding, Diagnosis, and Treatment Approaches,” International Journal of Molecular Sciences 18, no. 7 (2017): 1384.

[66] M. D. Sweeney, Z. Zhao, A. Montagne, A. R. Nelson, and B. V. Zlokovic, “Blood-Brain Barrier: From Physiology to Disease and Back,” Physiological Reviews 99, no. 1 (2019): 21–78.

[67] W. Loscher and A. Friedman, “Structural, Molecular, and Functional Alterations of the Blood-Brain Barrier During Epileptogenesis and Epilepsy: A Cause, Consequence, or Both?,” International Journal of Molecular Sciences 21, no. 2 (2020): 591.

[68] C. P. Profaci, R. N. Munji, R. S. Pulido, and R. Daneman, “The Blood-Brain Barrier in Health and Disease: Important Unanswered Questions,” Journal of Experimental Medicine 217, no. 4 (2020): e20190062.

[69] A. Dadas and D. Janigro, “Breakdown of Blood Brain Barrier as a Mechanism of Post-Traumatic Epilepsy,” Neurobiology of Disease 123 (2019): 20–26.

[70] Y. Reiss, S. Bauer, B. David, et al., “The Neurovasculature as a Target in Temporal Lobe Epilepsy,” Brain Pathology 33, no. 2 (2023): e13147.

[71] W. C. Meijer and J. A. Gorter, “Role of Blood-Brain Barrier Dysfunction in the Development of Poststroke Epilepsy,” Epilepsia 65, no. 9 (2024): 2519–2536.

[72] C. Zeng, P. Zhou, T. Jiang, et al., “Upregulation and Diverse Roles of TRPC3 and TRPC6 in Synaptic Reorganization of the Mossy Fiber Pathway in Temporal Lobe Epilepsy,” Molecular Neurobiology 52, no. 1 (2015): 562–572.

[73] G. K. Silva-Cardoso, V. K. Boda, W. Li, and P. N'Gouemo, “Inhibition of TRPC3 Channels Suppresses Seizure Susceptibility in the Genetically-Epilepsy Prone Rats,” European Journal of Pharmacology 977 (2024): 176722.

[74] S. J. Min and T. C. Kang, “Positive Feedback Role of TRPC3 in TNF-Alpha-Mediated Vasogenic Edema Formation Induced by Status Epilepticus Independent of ET(B) Receptor Activation,” Neuroscience 337 (2016): 37–47.

[75] Z. Chen, M. J. Brodie, D. Liew, and P. Kwan, “Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study,” JAMA Neurology 75, no. 3 (2018): 279–286.

[76] J. Fawcett, S. Davis, and M. Manford, “Further Advances in Epilepsy,” Journal of Neurology 270, no. 11 (2023): 5655–5670.

[77] G. Dini, E. Tulli, and G. B. Dell'Isola, “Improving Therapy of Pharmacoresistant Epilepsies: The Role of Fenfluramine,” Frontiers in Pharmacology 13 (2022): 832929.

[78] M. Ozarowski, T. M. Karpinski, A. Zielinska, E. B. Souto, and K. Wielgus, “Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action,” International Journal of Molecular Sciences 22, no. 9 (2021): 4294.

[79] W. Loscher, G. J. Sills, and H. S. White, “The Ups and Downs of Alkyl-Carbamates in Epilepsy Therapy: How Does Cenobamate Differ?,” Epilepsia 62, no. 3 (2021): 596–614.

[80] S. Lattanzi, F. Brigo, E. Trinka, et al., “Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis,” Drugs 78, no. 17 (2018): 1791–1804.

[81] C. Ibeas Bih, T. Chen, A. V. Nunn, M. Bazelot, M. Dallas, and B. J. Whalley, “Molecular Targets of Cannabidiol in Neurological Disorders,” Neurotherapeutics 12, no. 4 (2015): 699–730.

[82] R. Roberti, C. De Caro, L. F. Iannone, G. Zaccara, S. Lattanzi, and E. Russo, “Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug-Drug Interactions and Tolerability,” CNS Drugs 35, no. 6 (2021): 609–618.

[83] J. E. Frampton, “Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes,” Drugs 83, no. 10 (2023): 923–934.

[84] M. Guignet, A. Campbell, and H. S. White, “Cenobamate (XCOPRI): Can Preclinical and Clinical Evidence Provide Insight Into Its Mechanism of Action?,” Epilepsia 61, no. 11 (2020): 2329–2339.

[85] L. Taylor, B. Gidal, G. Blakey, B. Tayo, and G. Morrison, “A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects,” CNS Drugs 32, no. 11 (2018): 1053–1067.

[86] E. Yang, J. Sunwoo, K. Y. Huh, et al., “Pharmacokinetics and Safety of Cenobamate, a Novel Antiseizure Medication, in Healthy Japanese, and an Ethnic Comparison With Healthy Non-Japanese,” Clinical and Translational Science 15, no. 2 (2022): 490–500.

[87] V. Franco and E. Perucca, “Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy,” Drugs 79, no. 13 (2019): 1435–1454.

[88] L. Vernillet, S. A. Greene, and M. Kamin, “Pharmacokinetics of Cenobamate: Results From Single and Multiple Oral Ascending-Dose Studies in Healthy Subjects,” Clinical Pharmacology in Drug Development 9, no. 4 (2020): 428–443.

[89] A. Verrotti, S. Lattanzi, F. Brigo, and G. Zaccara, “Pharmacodynamic Interactions of Antiepileptic Drugs: From Bench to Clinical Practice,” Epilepsy & Behavior 104, no. pt. A (2020): 106939.

[90] E. Perucca and M. Bialer, “Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications,” CNS Drugs 34, no. 8 (2020): 795–800.

[91] L. Vernillet, S. A. Greene, H. W. Kim, S. M. Melnick, and K. Glenn, “Mass Balance, Metabolism, and Excretion of Cenobamate, a New Antiepileptic Drug, After a Single Oral Administration in Healthy Male Subjects,” European Journal of Drug Metabolism and Pharmacokinetics 45, no. 4 (2020): 513–522.

[92] K. Borowicz-Reutt, J. Czernia, and M. Krawczyk, “CBD in the Treatment of Epilepsy,” Molecules 29, no. 9 (2024): 1981.

[93] O. Devinsky, J. H. Cross, L. Laux, et al., “Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome,” New England Journal of Medicine 376, no. 21 (2017): 2011–2020.

[94] E. A. Thiele, E. D. Marsh, J. A. French, et al., “Cannabidiol in Patients With Seizures Associated With Lennox-Gastaut Syndrome (GWPCARE4): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial,” Lancet 391, no. 10125 (2018): 1085–1096.

[95] E. A. Thiele, E. M. Bebin, H. Bhathal, et al., “Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial,” JAMA Neurology 78, no. 3 (2021): 285–292.

[96] S. S. Chung, J. A. French, J. Kowalski, et al., “Randomized Phase 2 Study of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures,” Neurology 94, no. 22 (2020): e2311–e2322.

[97] A. Fazlollahi, M. Zahmatyar, M. ZareDini, et al., “Adverse Events of Cannabidiol Use in Patients With Epilepsy: A Systematic Review and Meta-Analysis,” JAMA Network Open 6, no. 4 (2023): e239126.

[98] G. L. Krauss, P. Klein, C. Brandt, et al., “Safety and Efficacy of Adjunctive Cenobamate (YKP3089) in Patients With Uncontrolled Focal Seizures: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Dose-Response Trial,” Lancet Neurology 19, no. 1 (2020): 38–48.

[99] J. Cloyd, S. Haut, E. Carrazana, and A. L. Rabinowicz, “Overcoming the Challenges of Developing an Intranasal Diazepam Rescue Therapy for the Treatment of Seizure Clusters,” Epilepsia 62, no. 4 (2021): 846–856.

[100] Y. Dai, Y. Wang, Z. Li, et al., “Optimized Stereo-Electroencephalography-Guided Three-Dimensional Radiofrequency Thermocoagulation for Hypothalamic Hamartomas-Related Epilepsy: A Single-Center Experience in 69 Patients,” CNS Neuroscience & Therapeutics 31, no. 6 (2025): e70462.

[101] J. H. Cross, B. S. Galer, and A. Gil-Nagel, “Impact of Fenfluramine on the Expected SUDEP Mortality Rates in Patients With Dravet Syndrome,” Seizure: The Journal of the British Epilepsy Association 93 (2021): 154–159.

[102] K. G. Knupp, I. E. Scheffer, B. Ceulemans, et al., “Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial,” JAMA Neurology 79, no. 6 (2022): 554–564.

[103] L. Lagae, A. S. Schoonjans, A. R. Gammaitoni, B. S. Galer, and B. Ceulemans, “A Pilot, Open-Label Study of the Effectiveness and Tolerability of Low-Dose ZX008 (Fenfluramine HCl) in Lennox-Gastaut Syndrome,” Epilepsia 59, no. 10 (2018): 1881–1888.

[104] L. Lagae, J. Sullivan, K. Knupp, et al., “Fenfluramine Hydrochloride for the Treatment of Seizures in Dravet Syndrome: A Randomised, Double-Blind, Placebo-Controlled Trial,” Lancet 394, no. 10216 (2019): 2243–2254.

[105] R. Nabbout, A. Mistry, S. Zuberi, et al., “Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial,” JAMA Neurology 77, no. 3 (2020): 300–308.

[106] N. Specchio, N. Pietrafusa, V. Doccini, et al., “Efficacy and Safety of Fenfluramine Hydrochloride for the Treatment of Seizures in Dravet Syndrome: A Real-World Study,” Epilepsia 61, no. 11 (2020): 2405–2414.

[107] J. Sullivan, I. E. Scheffer, L. Lagae, et al., “Fenfluramine HCl (Fintepla(R)) Provides Long-Term Clinically Meaningful Reduction in Seizure Frequency: Analysis of an Ongoing Open-Label Extension Study,” Epilepsia 61, no. 11 (2020): 2396–2404.

[108] K. I. Bishop, P. K. Isquith, G. A. Gioia, et al., “Improved Everyday Executive Functioning Following Profound Reduction in Seizure Frequency With Fenfluramine: Analysis From a Phase 3 Long-Term Extension Study in Children/Young Adults With Dravet Syndrome,” Epilepsy & Behavior 121, no. pt. A (2021): 108024.

[109] J. Sullivan, N. Specchio, O. Devinsky, et al., “Fenfluramine Significantly Reduces Day-to-Day Seizure Burden by Increasing Number of Seizure-Free Days and Time Between Seizures in Patients With Dravet Syndrome: A Time-to-Event Analysis,” Epilepsia 63, no. 1 (2022): 130–138.

[110] K. G. Knupp, I. E. Scheffer, B. Ceulemans, et al., “Fenfluramine Provides Clinically Meaningful Reduction in Frequency of Drop Seizures in Patients With Lennox-Gastaut Syndrome: Interim Analysis of an Open-Label Extension Study,” Epilepsia 64, no. 1 (2023): 139–151.

[111] S. Patel, K. R. Geenen, D. Dowless, P. L. Bruno, and E. A. Thiele, “Follow-Up to Low-Dose Fenfluramine for Sunflower Syndrome: A Non-Randomized Controlled Trial,” Developmental Medicine and Child Neurology 65, no. 7 (2023): 961–967.

[112] K. I. Bishop, P. K. Isquith, G. A. Gioia, et al., “Fenfluramine Treatment Is Associated With Improvement in Everyday Executive Function in Preschool-Aged Children (<5 Years) With Dravet Syndrome: A Critical Period for Early Neurodevelopment,” Epilepsy & Behavior 138 (2023): 108994.

[113] J. M. Cunha, E. A. Carlini, A. E. Pereira, et al., “Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients,” Pharmacology 21, no. 3 (1980): 175–185.

[114] E. A. Carlini and J. M. Cunha, “Hypnotic and Antiepileptic Effects of Cannabidiol,” Journal of Clinical Pharmacology 21, no. S1 (1981): 417S–427S.

[115] O. Devinsky, E. Marsh, D. Friedman, et al., “Cannabidiol in Patients With Treatment-Resistant Epilepsy: An Open-Label Interventional Trial,” Lancet Neurology 15, no. 3 (2016): 270–278.

[116] O. Devinsky, A. D. Patel, E. A. Thiele, et al., “Randomized, Dose-Ranging Safety Trial of Cannabidiol in Dravet Syndrome,” Neurology 90, no. 14 (2018): e1204–e1211.

[117] O. Devinsky, A. D. Patel, J. H. Cross, et al., “Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome,” New England Journal of Medicine 378, no. 20 (2018): 1888–1897.

[118] J. P. Szaflarski, E. M. Bebin, G. Cutter, et al., “Cannabidiol Improves Frequency and Severity of Seizures and Reduces Adverse Events in an Open-Label Add-On Prospective Study,” Epilepsy & Behavior 87 (2018): 131–136.

[119] O. Devinsky, R. Nabbout, I. Miller, et al., “Long-Term Cannabidiol Treatment in Patients With Dravet Syndrome: An Open-Label Extension Trial,” Epilepsia 60, no. 2 (2019): 294–302.

[120] E. Thiele, E. Marsh, M. Mazurkiewicz-Beldzinska, et al., “Cannabidiol in Patients With Lennox-Gastaut Syndrome: Interim Analysis of an Open-Label Extension Study,” Epilepsia 60, no. 3 (2019): 419–428.

[121] T. E. Gaston, M. Szaflarski, B. Hansen, E. M. Bebin, J. P. Szaflarski, and U. C. Program, “Quality of Life in Adults Enrolled in an Open-Label Study of Cannabidiol (CBD) for Treatment-Resistant Epilepsy,” Epilepsy & Behavior 95 (2019): 10–17.

[122] L. C. Laux, E. M. Bebin, D. Checketts, et al., “Long-Term Safety and Efficacy of Cannabidiol in Children and Adults With Treatment Resistant Lennox-Gastaut Syndrome or Dravet Syndrome: Expanded Access Program Results,” Epilepsy Research 154 (2019): 13–20.

[123] A. Mitelpunkt, U. Kramer, M. Hausman Kedem, et al., “The Safety, Tolerability, and Effectiveness of PTL-101, an Oral Cannabidiol Formulation, in Pediatric Intractable Epilepsy: A Phase II, Open-Label, Single-Center Study,” Epilepsy & Behavior 98, no. pt. A (2019): 233–237.

[124] M. D. Thompson, R. C. Martin, L. P. Grayson, et al., “Cognitive Function and Adaptive Skills After a One-Year Trial of Cannabidiol (CBD) in a Pediatric Sample With Treatment-Resistant Epilepsy,” Epilepsy & Behavior 111 (2020): 107299.

[125] I. Miller, I. E. Scheffer, B. Gunning, et al., “Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial,” JAMA Neurology 77, no. 5 (2020): 613–621.

[126] A. D. Patel, M. Mazurkiewicz-Beldzinska, R. F. Chin, et al., “Long-Term Safety and Efficacy of Add-On Cannabidiol in Patients With Lennox-Gastaut Syndrome: Results of a Long-Term Open-Label Extension Trial,” Epilepsia 62, no. 9 (2021): 2228–2239.

[127] M. Privitera, H. Bhathal, M. Wong, et al., “Time to Onset of Cannabidiol (CBD) Treatment Effect in Lennox-Gastaut Syndrome: Analysis From Two Randomized Controlled Trials,” Epilepsia 62, no. 5 (2021): 1130–1140.

[128] I. E. Scheffer, J. J. Halford, I. Miller, et al., “Add-On Cannabidiol in Patients With Dravet Syndrome: Results of a Long-Term Open-Label Extension Trial,” Epilepsia 62, no. 10 (2021): 2505–2517.

[129] I. E. Scheffer, J. Hulihan, J. Messenheimer, et al., “Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial,” JAMA Network Open 4, no. 9 (2021): e2123930.

[130] K. A. Klotz, D. Grob, J. Schonberger, et al., “Effect of Cannabidiol on Interictal Epileptiform Activity and Sleep Architecture in Children With Intractable Epilepsy: A Prospective Open-Label Study,” CNS Drugs 35, no. 11 (2021): 1207–1215.

[131] E. A. Thiele, E. M. Bebin, F. Filloux, et al., “Long-Term Cannabidiol Treatment for Seizures in Patients With Tuberous Sclerosis Complex: An Open-Label Extension Trial,” Epilepsia 63, no. 2 (2022): 426–439.

[132] J. Y. Wu, H. R. Cock, O. Devinsky, et al., “Time to Onset of Cannabidiol Treatment Effect and Resolution of Adverse Events in Tuberous Sclerosis Complex: Post Hoc Analysis of Randomized Controlled Phase 3 Trial GWPCARE6,” Epilepsia 63, no. 5 (2022): 1189–1199.

[133] C. E. Navarro, “Cannabis-Based Magistral Formulation Is Highly Effective as an Adjuvant Treatment in Drug-Resistant Focal Epilepsy in Adult Patients: An Open-Label Prospective Cohort Study,” Neurological Sciences 44, no. 1 (2023): 297–304.

[134] D. G. A. Kasteleijn-Nolst Trenite, B. D. DiVentura, J. R. Pollard, G. L. Krauss, S. Mizne, and J. A. French, “Suppression of the Photoparoxysmal Response in Photosensitive Epilepsy With Cenobamate (YKP3089),” Neurology 93, no. 6 (2019): e559–e567.

[135] G. L. Krauss, P. Klein, C. Brandt, et al., “Safety and Efficacy of Adjunctive Cenobamate (YKP3089) in Patients With Uncontrolled Focal Seizures: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Dose-Response Trial,” Lancet Neurol 19, no. 1 (2020): 38–48.

[136] M. R. Sperling, P. Klein, S. Aboumatar, et al., “Cenobamate (YKP3089) as Adjunctive Treatment for Uncontrolled Focal Seizures in a Large, Phase 3, Multicenter, Open-Label Safety Study,” Epilepsia 61, no. 6 (2020): 1099–1108.

[137] J. A. French, S. S. Chung, G. L. Krauss, et al., “Long-Term Safety of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures: Open-Label Extension of a Randomized Clinical Study,” Epilepsia 62, no. 9 (2021): 2142–2150.

[138] R. Elizebath, E. Zhang, P. Coe, E. G. Gutierrez, J. Yang, and G. L. Krauss, “Cenobamate Treatment of Focal-Onset Seizures: Quality of Life and Outcome During up to Eight Years of Treatment,” Epilepsy & Behavior 116 (2021): 107796.

[139] J. W. Sander, W. E. Rosenfeld, J. J. Halford, B. J. Steinhoff, V. Biton, and M. Toledo, “Long-Term Individual Retention With Cenobamate in Adults With Focal Seizures: Pooled Data From the Clinical Development Program,” Epilepsia 63, no. 1 (2022): 139–149.

[140] B. J. Steinhoff, E. Ben-Menachem, C. Brandt, et al., “Onset of Efficacy and Adverse Events During Cenobamate Titration Period,” Acta Neurologica Scandinavica 146, no. 3 (2022): 265–275.

[141] P. Klein, S. Aboumatar, C. Brandt, et al., “Long-Term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures,” Neurology 99, no. 10 (2022): e989–e998.

[142] J. Xu, W. Wei, Y. Liu, H. Ye, and X. Liu, “Efficacy and Safety of Adjunctive Cenobamate Based on Patient Etiology: Post-Hoc Analysis of YKP3089C017 Randomized Clinical Trial,” Seizure: The Journal of the British Epilepsy Association 118 (2024): 95–102.

[143] G. L. Krauss, S. S. Chung, L. Ferrari, S. Stern, and W. E. Rosenfeld, “Cognitive and Psychiatric Adverse Events During Adjunctive Cenobamate Treatment in Phase 2 and Phase 3 Clinical Studies,” Epilepsy & Behavior 151 (2024): 109605.

[144] P. Landazuri, J. J. Cheng, E. Leuthardt, et al., “Interstitial Thermal Therapy in Mesial Temporal Lobe Epilepsy,” JAMA Neurology 82, no. 9 (2025): 915–924.

[145] J. Mo, Z. Guo, X. Wang, et al., “Magnetic Resonance-Guided Laser Interstitial Thermal Therapy vs. Open Surgery for Drug-Resistant Mesial Temporal Lobe Epilepsy: A Propensity Score Matched Retrospective Cohort Study,” International Journal of Surgery 110, no. 1 (2024): 306–314.

[146] B. Esmaeili, S. Hakimian, A. L. Ko, et al., “Epilepsy-Related Mortality After Laser Interstitial Thermal Therapy in Patients With Drug-Resistant Epilepsy,” Neurology 101, no. 13 (2023): e1359–e1363.

[147] R. M. McCormack, A. S. Chandran, S. D. Lhatoo, et al., “Laser Ablation of Periventricular Nodular Heterotopia for Medically Refractory Epilepsy,” Annals of Neurology 96, no. 6 (2024): 1174–1184.

[148] B. E. Youngerman, M. A. Banu, F. Khan, et al., “Long-Term Outcomes of Mesial Temporal Laser Interstitial Thermal Therapy for Drug-Resistant Epilepsy and Subsequent Surgery for Seizure Recurrence: A Multi-Centre Cohort Study,” Journal of Neurology, Neurosurgery, and Psychiatry 94, no. 11 (2023): 879–886.

[149] D. J. Aum, R. A. Reynolds, S. McEvoy, et al., “Surgical Outcomes of Open and Laser Interstitial Thermal Therapy Approaches for Corpus Callosotomy in Pediatric Epilepsy,” Epilepsia 64, no. 9 (2023): 2274–2285.

[150] O. Yossofzai, S. Stone, J. Madsen, et al., “Seizure Outcome of Pediatric Magnetic Resonance-Guided Laser Interstitial Thermal Therapy Versus Open Surgery: A Matched Noninferiority Cohort Study,” Epilepsia 64, no. 1 (2023): 114–126.

[151] M. J. Kim, B. Hwang, D. Mampre, et al., “Ablation of Apparent Diffusion Coefficient Hyperintensity Clusters in Mesial Temporal Lobe Epilepsy Improves Seizure Outcomes After Laser Interstitial Thermal Therapy,” Epilepsia 64, no. 3 (2023): 654–666.

[152] A. M. Kanner, L. T. Irving, I. Cajigas, et al., “Long-Term Seizure and Psychiatric Outcomes Following Laser Ablation of Mesial Temporal Structures,” Epilepsia 63, no. 4 (2022): 812–823.

[153] B. Yang, C. Zhang, X. Wang, et al., “Laser Interstitial Thermal Therapy in the Management of Bottom-of-Sulcus Dysplasia-Related Epilepsy,” Annals of Clinical and Translational Neurology 12, no. 1 (2025): 110–120.

[154] F. R. Ekman, J. Gonzalez-Martinez, S. Haahr Nielsen, R. Rasmussen, and D. Nilsson, “Technique, Safety Profile, and Seizure Outcomes After Laser Ablation for Insular Epilepsy: A Multicenter Cohort Study,” Journal of Neurosurgery 144 (2025): 55–62.

[155] H. W. Phillips, J. L. Hect, E. Harford, E. Pan, and T. J. Abel, “Comparison of Magnetic Resonance-Guided Laser Interstitial Thermal Therapy Corpus Callosum Ablation to Open Microsurgical Corpus Callosotomy: A Single-Center Retrospective Cohort Study,” Epilepsia Open 9, no. 1 (2024): 96–105.

[156] Y. Yao, X. Wang, W. Hu, et al., “Magnetic Resonance-Guided Laser Interstitial Thermal Therapy for Hypothalamic Hamartoma: Surgical Approach and Treatment Outcomes,” Journal of Clinical Medicine 11, no. 21 (2022): 6579.

[157] A. N. Mallela, J. L. Hect, H. Abou-Al-Shaar, E. Akwayena, and T. J. Abel, “Stereotactic Laser Interstitial Thermal Therapy Corpus Callosotomy for the Treatment of Pediatric Drug-Resistant Epilepsy,” Epilepsia Open 7, no. 1 (2022): 75–84.

[158] A. Athreya, R. E. Matthews, D. L. Drane, et al., “Withdrawal of Antiseizure Medications After MRI-Guided Laser Interstitial Thermal Therapy in Extra-Temporal Lobe Epilepsy,” Seizure: The Journal of the British Epilepsy Association 110 (2023): 86–92.

[159] V. M. Ravindra, L. Ruggieri, N. Gadgil, et al., “An Initial Experience of Completion Hemispherotomy via Magnetic Resonance-Guided Laser Interstitial Therapy,” Stereotactic and Functional Neurosurgery 101, no. 3 (2023): 179–187.

[160] Y. Shan, J. Shi, T. Wang, et al., “Optimized Stereoelectroencephalography-Guided Thermocoagulation Versus Anterior Temporal Lobectomy in Mesial Temporal Epilepsy: A Pilot Randomized Controlled Study,” Journal of Advanced Research 81 (2026): 955–965.

[161] E. Cockle, C. B. Malpas, H. Coleman, et al., “Neuropsychological Outcomes After Stereo-EEG Radiofrequency Thermocoagulation,” Neurology 103, no. 11 (2024): e209815.

[162] H. Catenoix, F. Mauguiere, M. Guenot, et al., “SEEG-Guided Thermocoagulations: A Palliative Treatment of Nonoperable Partial Epilepsies,” Neurology 71, no. 21 (2008): 1719–1726.

[163] M. Cossu, D. Fuschillo, F. Cardinale, et al., “Stereo-EEG-Guided Radio-Frequency Thermocoagulations of Epileptogenic Grey-Matter Nodular Heterotopy,” Journal of Neurology, Neurosurgery, and Psychiatry 85, no. 6 (2014): 611–617.

[164] P. C. Reinacher, J. Jacobs, M. J. Shah, et al., “Long-Term Outcomes of Stereotactic Radiofrequency Ablation in Hypothalamic Hamartomas: A Single-Center Experience,” Epilepsia 67 (2026): 96–108.

[165] L. De Clerck, V. Pelliccia, R. Carron, et al., “Stereoelectroencephalographic Thermocoagulation in FLNA-Positive Heterotopia: Is It an Effective Treatment?,” Epilepsia 66, no. 2 (2025): e29–e34.

[166] H. Shirozu, H. Masuda, and S. Kameyama, “Long-Term Seizure Outcomes in Patients With Hypothalamic Hamartoma Treated by Stereotactic Radiofrequency Thermocoagulation,” Epilepsia 62, no. 11 (2021): 2697–2706.

[167] N. Mullatti, E. Landre, C. Mellerio, et al., “Stereotactic Thermocoagulation for Insular Epilepsy: Lessons From Successes and Failures,” Epilepsia 60, no. 8 (2019): 1565–1579.

[168] M. Sonoda, H. Masuda, H. Shirozu, et al., “Predictors of Cognitive Function in Patients With Hypothalamic Hamartoma Following Stereotactic Radiofrequency Thermocoagulation Surgery,” Epilepsia 58, no. 9 (2017): 1556–1565.

[169] P. Dimova, L. de Palma, A. S. Job-Chapron, L. Minotti, D. Hoffmann, and P. Kahane, “Radiofrequency Thermocoagulation of the Seizure-Onset Zone During Stereoelectroencephalography,” Epilepsia 58, no. 3 (2017): 381–392.

[170] P. Bourdillon, J. Isnard, H. Catenoix, et al., “Stereo Electroencephalography-Guided Radiofrequency Thermocoagulation (SEEG-Guided RF-TC) in Drug-Resistant Focal Epilepsy: Results From a 10-Year Experience,” Epilepsia 58, no. 1 (2017): 85–93.

[171] M. Guenot, J. Isnard, P. Ryvlin, C. Fischer, F. Mauguiere, and M. Sindou, “SEEG-Guided RF Thermocoagulation of Epileptic Foci: Feasibility, Safety, and Preliminary Results,” Epilepsia 45, no. 11 (2004): 1368–1374.

[172] T. Luo, X. Wang, J. Wang, et al., “Optimization and High-Density Array of Stereoelectroencephalography-Guided Radiofrequency Thermocoagulation for the Treatment of Pediatric Tuberous Sclerosis Complex With Epilepsy,” CNS Neuroscience & Therapeutics 28, no. 5 (2022): 724–731.

[173] A. Moles, M. Guenot, S. Rheims, et al., “SEEG-Guided Radiofrequency Coagulation (SEEG-Guided RF-TC) Versus Anterior Temporal Lobectomy (ATL) in Temporal Lobe Epilepsy,” Journal of Neurology 265, no. 9 (2018): 1998–2004.

[174] S. Jean, R. Jiang, Y. Dai, et al., “Optimizing Outcomes in Drug-Resistant Mesial Temporal Lobe Epilepsy Patients Undergoing Stereoelectroencephalography-Guided Radiofrequency Thermocoagulation,” Therapeutic Advances in Neurological Disorders 17 (2024): 17562864241286867.

[175] Q. Liu, Y. Cai, Z. Mao, et al., “SEEG-RFTC in Patients With Refractory Focal Epilepsy: Real-World Outcomes From 121 Cases,” Annals of Clinical and Translational Neurology 11, no. 8 (2024): 1999–2007.

[176] S. Kameyama, H. Murakami, H. Masuda, and I. Sugiyama, “Minimally Invasive Magnetic Resonance Imaging-Guided Stereotactic Radiofrequency Thermocoagulation for Epileptogenic Hypothalamic Hamartomas,” Neurosurgery 65, no. 3 (2009): 438–449.

[177] C. Perez-Enriquez, L. Panades-de Oliveira, and R. M. Manero, “Cognitive Outcome After Stereo-Electroencephalography-Guided Radiofrequency Thermocoagulation in Temporal Lobe Epilepsy,” Journal of Neurosurgery 142, no. 2 (2025): 279–287.

[178] K. T. Minkin, K. R. Gabrovski, Y. T. Milenova, P. A. Karazapryanov, S. S. Sirakov, and P. S. Dimova, “Monopolar Stereoelectroencephalography-Guided Radiofrequency Thermocoagulation,” Journal of Neurosurgery 140, no. 4 (2024): 1129–1136.

[179] L. P. Oliveira, C. Perez-Enriquez, A. Barguilla, et al., “Stereo-Electroencephalography-Guided Radiofrequency Thermocoagulation in Patients With MRI-Negative Focal Epilepsy,” Journal of Neurosurgery 138, no. 3 (2023): 837–846.

[180] C. Y. Lee, H. T. Li, T. Wu, M. Y. Cheng, S. N. Lim, and S. T. Lee, “Efficacy of Limited Hippocampal Radiofrequency Thermocoagulation for Mesial Temporal Lobe Epilepsy,” Journal of Neurosurgery 131, no. 3 (2019): 781–789.

[181] H. Shirozu, H. Masuda, Y. Ito, M. Sonoda, and S. Kameyama, “Stereotactic Radiofrequency Thermocoagulation for Giant Hypothalamic Hamartoma,” Journal of Neurosurgery 125, no. 4 (2016): 812–821.

[182] S. Kameyama, H. Shirozu, H. Masuda, Y. Ito, M. Sonoda, and K. Akazawa, “MRI-Guided Stereotactic Radiofrequency Thermocoagulation for 100 Hypothalamic Hamartomas,” Journal of Neurosurgery 124, no. 5 (2016): 1503–1512.

[183] M. Cossu, D. Fuschillo, G. Casaceli, et al., “Stereoelectroencephalography-Guided Radiofrequency Thermocoagulation in the Epileptogenic Zone: A Retrospective Study on 89 Cases,” Journal of Neurosurgery 123, no. 6 (2015): 1358–1367.

[184] K. Li, J. Shi, P. Wei, X. He, Y. Shan, and G. Zhao, “Stereo-Electroencephalography-Guided Three-Dimensional Radiofrequency Thermocoagulation for Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis: A Retrospective Study With Long-Term Follow-Up,” Epilepsia Open 9, no. 3 (2024): 918–925.

[185] H. Shirozu, H. Masuda, and S. Kameyama, “Repeat Stereotactic Radiofrequency Thermocoagulation in Patients With Hypothalamic Hamartoma and Seizure Recurrence,” Epilepsia Open 5, no. 1 (2020): 107–120.

[186] R. Slegers, L. Wagner, S. van Kuijk, et al., “Stereo-Electroencephalography-Guided Radiofrequency Thermocoagulation Restricted to Periventricular Nodular Heterotopias in Patients With Drug-Resistant Epilepsy: A Single Center Experience,” Seizure: The Journal of the British Epilepsy Association 121 (2024): 105–113.

[187] B. M. Uthman, B. J. Wilder, E. J. Hammond, and S. A. Reid, “Efficacy and Safety of Vagus Nerve Stimulation in Patients With Complex Partial Seizures,” Epilepsia 31, no. S2 (1990): S44–S50.

[188] B. M. Uthman, B. J. Wilder, J. K. Penry, et al., “Treatment of Epilepsy by Stimulation of the Vagus Nerve,” Neurology 43, no. 7 (1993): 1338–1345.

[189] H. J. Landy, R. E. Ramsay, J. Slater, R. R. Casiano, and R. Morgan, “Vagus Nerve Stimulation for Complex Partial Seizures: Surgical Technique, Safety, and Efficacy,” Journal of Neurosurgery 78, no. 1 (1993): 26–31.

[190] E. Ben-Menachem, R. Manon-Espaillat, and R. Ristanovic, “Vagus Nerve Stimulation for Treatment of Partial Seizures: 1. A Controlled Study of Effect on Seizures. First International Vagus Nerve Stimulation Study Group,” Epilepsia 35, no. 3 (1994): 616–626.

[191] R. E. Ramsay, B. M. Uthman, L. E. Augustinsson, et al., “Vagus Nerve Stimulation for Treatment of Partial Seizures: 2. Safety, Side Effects, and Tolerability. First International Vagus Nerve Stimulation Study Group,” Epilepsia 35, no. 3 (1994): 627–636.

[192] The Vagus Nerve Stimulation Study Group. “A Randomized Controlled Trial of Chronic Vagus Nerve Stimulation for Treatment of Medically Intractable Seizures,” Neurology 45, no. 2 (1995): 224–230.

[193] A. Handforth, C. M. DeGiorgio, S. C. Schachter, et al., “Vagus Nerve Stimulation Therapy for Partial-Onset Seizures: A Randomized Active-Control Trial,” Neurology 51, no. 1 (1998): 48–55.

[194] D. Labar, J. Murphy, and E. Tecoma, “Vagus Nerve Stimulation for Medication-Resistant Generalized Epilepsy. E04 VNS Study Group,” Neurology 52, no. 7 (1999): 1510–1512.

[195] A. P. Parker, C. E. Polkey, C. D. Binnie, C. Madigan, C. D. Ferrie, and R. O. Robinson, “Vagal Nerve Stimulation in Epileptic Encephalopathies,” Pediatrics 103, no. pt. 1 (1999): 778–782.

[196] A. P. Amar, C. M. DeGiorgio, W. B. Tarver, and M. L. Apuzzo, “Long-Term Multicenter Experience With Vagus Nerve Stimulation for Intractable Partial Seizures: Results of the XE5 Trial,” Stereotactic and Functional Neurosurgery 73, no. 1–4 (1999): 104–108.

[197] J. I. Sirven, M. Sperling, D. Naritoku, et al., “Vagus Nerve Stimulation Therapy for Epilepsy in Older Adults,” Neurology 54, no. 5 (2000): 1179–1182.

[198] C. M. DeGiorgio, S. C. Schachter, A. Handforth, et al., “Prospective Long-Term Study of Vagus Nerve Stimulation for the Treatment of Refractory Seizures,” Epilepsia 41, no. 9 (2000): 1195–1200.

[199] S. Hosain, B. Nikalov, C. Harden, M. Li, R. Fraser, and D. Labar, “Vagus Nerve Stimulation Treatment for Lennox-Gastaut Syndrome,” Journal of Child Neurology 15, no. 8 (2000): 509–512.

[200] M. Frost, J. Gates, S. L. Helmers, et al., “Vagus Nerve Stimulation in Children With Refractory Seizures Associated With Lennox-Gastaut Syndrome,” Epilepsia 42, no. 9 (2001): 1148–1152.

[201] J. Scherrmann, C. Hoppe, T. Kral, J. Schramm, and C. E. Elger, “Vagus Nerve Stimulation: Clinical Experience in a Large Patient Series,” Journal of Clinical Neurophysiology 18, no. 5 (2001): 408–414.

[202] N. Zamponi, F. Rychlicki, C. Cardinali, A. Luchetti, R. Trignani, and A. Ducati, “Intermittent Vagal Nerve Stimulation in Paediatric Patients: 1-Year Follow-Up,” Childs Nervous System 18, no. 1–2 (2002): 61–66.

[203] W. Koszewski, T. Bacia, and A. Rysz, “[Vagus Nerve Stimulation (VNS) in the Treatment of Drug-Resistant Epilepsy. A 4-Year Follow-Up Evaluation of VNS Treatment Efficacy],” Neurologia I Neurochirurgia Polska 37, no. 3 (2003): 573–586.

[204] S. Buoni, A. Mariottini, S. Pieri, et al., “Vagus Nerve Stimulation for Drug-Resistant Epilepsy in Children and Young Adults,” Brain & Development 26, no. 3 (2004): 158–163.

[205] M. D. Holmes, D. L. Silbergeld, D. Drouhard, A. J. Wilensky, and L. M. Ojemann, “Effect of Vagus Nerve Stimulation on Adults With Pharmacoresistant Generalized Epilepsy Syndromes,” Seizure: The Journal of the British Epilepsy Association 13, no. 5 (2004): 340–345.

[206] D. Labar, “Vagus Nerve Stimulation for 1 Year in 269 Patients on Unchanged Antiepileptic Drugs,” Seizure: The Journal of the British Epilepsy Association 13, no. 6 (2004): 392–398.

[207] K. Vonck, V. Thadani, K. Gilbert, et al., “Vagus Nerve Stimulation for Refractory Epilepsy: A Transatlantic Experience,” Journal of Clinical Neurophysiology 21, no. 4 (2004): 283–289.

[208] R. L. Huf, A. Mamelak, and K. Kneedy-Cayem, “Vagus Nerve Stimulation Therapy: 2-Year Prospective Open-Label Study of 40 Subjects With Refractory Epilepsy and Low IQ Who Are Living in Long-Term Care Facilities,” Epilepsy & Behavior 6, no. 3 (2005): 417–423.

[209] T. Hallbook, J. Lundgren, K. Stjernqvist, G. Blennow, L. G. Stromblad, and I. Rosen, “Vagus Nerve Stimulation in 15 Children With Therapy Resistant Epilepsy; Its Impact on Cognition, Quality of Life, Behaviour and Mood,” Seizure: The Journal of the British Epilepsy Association 14, no. 7 (2005): 504–513.

[210] T. Hallbook, J. Lundgren, S. Kohler, G. Blennow, L. G. Stromblad, and I. Rosen, “Beneficial Effects on Sleep of Vagus Nerve Stimulation in Children With Therapy Resistant Epilepsy,” European Journal of Paediatric Neurology 9, no. 6 (2005): 399–407.

[211] E. Santiago-Rodriguez, M. Alonso-Vanegas, L. Cardenas-Morales, T. Harmony, M. Bernardino, and A. Fernandez-Bouzas, “Effects of Two Different Cycles of Vagus Nerve Stimulation on Interictal Epileptiform Discharges,” Seizure: The Journal of the British Epilepsy Association 15, no. 8 (2006): 615–620.

[212] A. A. Wilfong and R. J. Schultz, “Vagus Nerve Stimulation for Treatment of Epilepsy in Rett Syndrome,” Developmental Medicine and Child Neurology 48, no. 8 (2006): 683–686.

[213] J. J. Ardesch, H. P. Buschman, L. J. Wagener-Schimmel, H. E. van der Aa, and G. Hageman, “Vagus Nerve Stimulation for Medically Refractory Epilepsy: A Long-Term Follow-Up Study,” Seizure: The Journal of the British Epilepsy Association 16, no. 7 (2007): 579–585.

[214] A. Abubakr and I. Wambacq, “Long-Term Outcome of Vagus Nerve Stimulation Therapy in Patients With Refractory Epilepsy,” Journal of Clinical Neuroscience 15, no. 2 (2008): 127–129.

[215] A. Shahwan, C. Bailey, W. Maxiner, and A. S. Harvey, “Vagus Nerve Stimulation for Refractory Epilepsy in Children: More to VNS Than Seizure Frequency Reduction,” Epilepsia 50, no. 5 (2009): 1220–1228.

[216] H. Wang, X. Chen, Z. Lin, et al., “Long-Term Effect of Vagus Nerve Stimulation on Interictal Epileptiform Discharges in Refractory Epilepsy,” Journal of the Neurological Sciences 284, no. 1–2 (2009): 96–102.

[217] E. Rossignol, A. Lortie, T. Thomas, et al., “Vagus Nerve Stimulation in Pediatric Epileptic Syndromes,” Seizure: The Journal of the British Epilepsy Association 18, no. 1 (2009): 34–37.

[218] K. Kostov, H. Kostov, and E. Tauboll, “Long-Term Vagus Nerve Stimulation in the Treatment of Lennox-Gastaut Syndrome,” Epilepsy & Behavior 16, no. 2 (2009): 321–324.

[219] R. E. Elliott, C. Carlson, S. P. Kalhorn, et al., “Refractory Epilepsy in Tuberous Sclerosis: Vagus Nerve Stimulation With or Without Subsequent Resective Surgery,” Epilepsy & Behavior 16, no. 3 (2009): 454–460.

[220] K. Muller, D. Fabo, L. Entz, et al., “Outcome of Vagus Nerve Stimulation for Epilepsy in Budapest,” Epilepsia 51, no. S3 (2010): 98–101.

[221] S. Klinkenberg, M. W. Aalbers, J. S. Vles, et al., “Vagus Nerve Stimulation in Children With Intractable Epilepsy: A Randomized Controlled Trial,” Developmental Medicine and Child Neurology 54, no. 9 (2012): 855–861.

[222] S. Klinkenberg, C. N. van den Bosch, H. J. Majoie, et al., “Behavioural and Cognitive Effects During Vagus Nerve Stimulation in Children With Intractable Epilepsy—A Randomized Controlled Trial,” European Journal of Paediatric Neurology 17, no. 1 (2013): 82–90.

[223] P. Ryvlin, F. G. Gilliam, D. K. Nguyen, et al., “The Long-Term Effect of Vagus Nerve Stimulation on Quality of Life in Patients With Pharmacoresistant Focal Epilepsy: The PuLsE (Open Prospective Randomized Long-Term Effectiveness) Trial,” Epilepsia 55, no. 6 (2014): 893–900.

[224] M. Vaiman, E. Heyman, and G. Lotan, “Neurological Results of the Modified Treatment of Epilepsy by Stimulation of the Vagus Nerve,” Childs Nervous System 33, no. 11 (2017): 2017–2022.

[225] R. Fisher, V. Salanova, T. Witt, et al., “Electrical Stimulation of the Anterior Nucleus of Thalamus for Treatment of Refractory Epilepsy,” Epilepsia 51, no. 5 (2010): 899–908.

[226] Y. S. Oh, H. J. Kim, K. J. Lee, Y. I. Kim, S. C. Lim, and Y. M. Shon, “Cognitive Improvement After Long-Term Electrical Stimulation of Bilateral Anterior Thalamic Nucleus in Refractory Epilepsy Patients,” Seizure: The Journal of the British Epilepsy Association 21, no. 3 (2012): 183–187.

[227] K. J. Lee, Y. M. Shon, and C. B. Cho, “Long-Term Outcome of Anterior Thalamic Nucleus Stimulation for Intractable Epilepsy,” Stereotactic and Functional Neurosurgery 90, no. 6 (2012): 379–385.

[228] V. Salanova, T. Witt, R. Worth, et al., “Long-Term Efficacy and Safety of Thalamic Stimulation for Drug-Resistant Partial Epilepsy,” Neurology 84, no. 10 (2015): 1017–1025.

[229] H. Herrman, A. Egge, A. E. Konglund, J. Ramm-Pettersen, E. Dietrichs, and E. Tauboll, “Anterior Thalamic Deep Brain Stimulation in Refractory Epilepsy: A Randomized, Double-Blinded Study,” Acta Neurologica Scandinavica 139, no. 3 (2019): 294–304.

[230] V. Salanova, M. R. Sperling, R. E. Gross, et al., “The SANTE Study at 10 Years of Follow-Up: Effectiveness, Safety, and Sudden Unexpected Death in Epilepsy,” Epilepsia 62, no. 6 (2021): 1306–1317.

[231] J. Peltola, A. J. Colon, J. Pimentel, et al., “Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Drug-Resistant Epilepsy in the MORE Multicenter Patient Registry,” Neurology 100, no. 18 (2023): e1852–e1865.

[232] M. J. Morrell, and RNS System in Epilepsy Study Group, “Responsive Cortical Stimulation for the Treatment of Medically Intractable Partial Epilepsy,” Neurology 77, no. 13 (2011): 1295–1304.

[233] C. N. Heck, D. King-Stephens, A. D. Massey, et al., “Two-Year Seizure Reduction in Adults With Medically Intractable Partial Onset Epilepsy Treated With Responsive Neurostimulation: Final Results of the RNS System Pivotal Trial,” Epilepsia 55, no. 3 (2014): 432–441.

[234] G. K. Bergey, M. J. Morrell, E. M. Mizrahi, et al., “Long-Term Treatment With Responsive Brain Stimulation in Adults With Refractory Partial Seizures,” Neurology 84, no. 8 (2015): 810–817.

[235] K. J. Meador, R. Kapur, D. W. Loring, A. M. Kanner, and M. J. Morrell, and RNS® System Pivotal Trial Investigators, “Quality of Life and Mood in Patients With Medically Intractable Epilepsy Treated With Targeted Responsive Neurostimulation,” Epilepsy & Behavior 45 (2015): 242–247.

[236] E. B. Geller, T. L. Skarpaas, R. E. Gross, et al., “Brain-Responsive Neurostimulation in Patients With Medically Intractable Mesial Temporal Lobe Epilepsy,” Epilepsia 58, no. 6 (2017): 994–1004.

[237] B. C. Jobst, R. Kapur, G. L. Barkley, et al., “Brain-Responsive Neurostimulation in Patients With Medically Intractable Seizures Arising From Eloquent and Other Neocortical Areas,” Epilepsia 58, no. 6 (2017): 1005–1014.

[238] V. Krishna, J. Mindel, F. Sammartino, et al., “A Phase 1 Open-Label Trial Evaluating Focused Ultrasound Unilateral Anterior Thalamotomy for Focal Onset Epilepsy,” Epilepsia 64, no. 4 (2023): 831–842.

[239] E. J. Bubrick, N. J. McDannold, J. Orozco, et al., “Transcranial Ultrasound Neuromodulation for Epilepsy: A Pilot Safety Trial,” Brain Stimulation 17, no. 1 (2024): 7–9.

[240] P. E. Penovich, V. R. Rao, L. Long, E. Carrazana, and A. L. Rabinowicz, “Benzodiazepines for the Treatment of Seizure Clusters,” CNS Drugs 38, no. 2 (2024): 125–140.

[241] J. Wheless, J. Peters, S. N. Misra, et al., “Comment on “Intranasal Midazolam Versus Intravenous/Rectal Benzodiazepines for Acute Seizure Control in Children: A Systematic Review and Meta-Analysis”,” Epilepsy & Behavior 128 (2022): 108550.

[242] R. E. Hogan, D. Tarquinio, M. R. Sperling, et al., “Pharmacokinetics and Safety of VALTOCO (NRL-1; Diazepam Nasal Spray) in Patients With Epilepsy During Seizure (Ictal/Peri-Ictal) and Nonseizure (Interictal) Conditions: A Phase 1, Open-Label Study,” Epilepsia 61, no. 5 (2020): 935–943.

[243] M. R. Sperling, J. W. Wheless, R. E. Hogan, et al., “Use of Second Doses of Valtoco(R) (Diazepam Nasal Spray) Across 24 Hours After the Initial Dose for Out-of-Hospital Seizure Clusters: Results From a Phase 3, Open-Label, Repeat-Dose Safety Study,” Epilepsia 63, no. 4 (2022): 836–843.

[244] F. Brigo, R. Nardone, F. Tezzon, and E. Trinka, “A Common Reference-Based Indirect Comparison Meta-Analysis of Buccal Versus Intranasal Midazolam for Early Status Epilepticus,” CNS Drugs 29, no. 9 (2015): 741–757.

[245] M. T. Wilson, S. Macleod, and M. E. O'Regan, “Nasal/Buccal Midazolam Use in the Community,” Archives of Disease in Childhood 89, no. 1 (2004): 50–51.

[246] B. E. Gidal, J. Ferry, L. Reyderman, and J. E. Pina-Garza, “Use of Extended-Release and Immediate-Release Anti-Seizure Medications With a Long Half-Life to Improve Adherence in Epilepsy: A Guide for Clinicians,” Epilepsy & Behavior 120 (2021): 107993.

[247] J. F. Tellez-Zenteno, L. Hernandez Ronquillo, F. Moien-Afshari, and S. Wiebe, “Surgical Outcomes in Lesional and Non-Lesional Epilepsy: A Systematic Review and Meta-Analysis,” Epilepsy Research 89, no. 2–3 (2010): 310–318.

[248] C. Hoppe, K. Beeres, J. A. Witt, R. Sassen, and C. Helmstaedter, “Clinical Adult Outcome 11–30 Years After Pediatric Epilepsy Surgery: Complications and Other Surgical Adverse Events, Seizure Control, and Cure of Epilepsy,” Epilepsia 64, no. 2 (2023): 335–347.

[249] J. Singh, J. S. Ebersole, and B. H. Brinkmann, “From Theory to Practical Fundamentals of Electroencephalographic Source Imaging in Localizing the Epileptogenic Zone,” Epilepsia 63, no. 10 (2022): 2476–2490.

[250] A. Soltani Khaboushan, A. Afrooghe, E. Ahmadi, et al., “Accuracy, Effectiveness, and Safety of Robot-Assisted Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy for Treatment of Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis,” World Neurosurgery 195 (2025): 123640.

[251] J. S. Duncan and K. Trimmel, “Advanced Neuroimaging Techniques in Epilepsy,” Current Opinion in Neurology 35, no. 2 (2022): 189–195.

[252] B. Frauscher, A. O. Rossetti, and S. Beniczky, “Recent Advances in Clinical Electroencephalography,” Current Opinion in Neurology 37, no. 2 (2024): 134–140.

[253] P. Nemtsas, G. Birot, F. Pittau, et al., “Source Localization of Ictal Epileptic Activity Based on High-Density Scalp EEG Data,” Epilepsia 58, no. 6 (2017): 1027–1036.

[254] Z. Wang, J. Guo, M. van 't Klooster, S. Hoogteijling, J. Jacobs, and M. Zijlmans, “Prognostic Value of Complete Resection of the High-Frequency Oscillation Area in Intracranial EEG: A Systematic Review and Meta-Analysis,” Neurology 102, no. 9 (2024): e209216.

[255] L. Noorlag, N. E. C. van Klink, K. Kobayashi, J. Gotman, K. P. J. Braun, and M. Zijlmans, “High-Frequency Oscillations in Scalp EEG: A Systematic Review of Methodological Choices and Clinical Findings,” Clinical Neurophysiology 137 (2022): 46–58.

[256] A. M. Bank, R. Kuzniecky, R. C. Knowlton, et al., “Structural Neuroimaging in Adults and Adolescents With Newly Diagnosed Focal Epilepsy: The Human Epilepsy Project,” Neurology 99, no. 19 (2022): e2181–e2187.

[257] T. Platt, M. E. Ladd, and D. Paech, “7 Tesla and Beyond: Advanced Methods and Clinical Applications in Magnetic Resonance Imaging,” Investigative Radiology 56, no. 11 (2021): 705–725.

[258] E. de Vries, C. Hagbohm, R. Ouellette, and T. Granberg, “Clinical 7 Tesla Magnetic Resonance Imaging: Impact and Patient Value in Neurological Disorders,” Journal of Internal Medicine 297, no. 3 (2025): 244–261.

[259] R. van Lanen, A. J. Colon, C. J. Wiggins, et al., “Ultra-High Field Magnetic Resonance Imaging in Human Epilepsy: A Systematic Review,” NeuroImage: Clinical 30 (2021): 102602.

[260] A. Sriwastwa, A. T. Trout, B. W. Mahoney, L. L. Wang, and J. L. Scheler, “Nuclear Medicine Imaging in Epilepsy,” Radiographics 45, no. 1 (2025): e240062.

[261] C. Z. Cankurtaran, J. Templer, S. K. Bandt, et al., “Multimodal Presurgical Evaluation of Medically Refractory Focal Epilepsy in Adults: An Update for Radiologists,” AJR American Journal of Roentgenology 219, no. 3 (2022): 488–500.

[262] M. K. Sidhu, J. S. Duncan, and J. W. Sander, “Neuroimaging in Epilepsy,” Current Opinion in Neurology 31, no. 4 (2018): 371–378.

[263] T. Traub-Weidinger, J. Arbizu, H. Barthel, et al., “EANM Practice Guidelines for an Appropriate Use of PET and SPECT for Patients With Epilepsy,” European Journal of Nuclear Medicine and Molecular Imaging 51, no. 7 (2024): 1891–1908.

[264] T. J. O'Brien, E. L. So, and B. P. Mullan, “Subtraction Ictal SPECT Co-Registered to MRI Improves Clinical Usefulness of SPECT in Localizing the Surgical Seizure Focus,” Neurology 50, no. 2 (1998): 445–454.

[265] M. Steinbrenner, J. S. Duncan, J. Dickson, et al., “Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography in Presurgical Evaluation of Patients With Epilepsy: A Multicenter Study,” Epilepsia 63, no. 5 (2022): 1238–1252.

[266] W. Huang, J. Zong, M. Li, T. F. Li, S. Pan, and Z. Xiao, “Challenges and Opportunities: Nanomaterials in Epilepsy Diagnosis,” ACS Nano 19, no. 17 (2025): 16224–16247.

[267] A. Lucas, A. Revell, and K. A. Davis, “Artificial Intelligence in Epilepsy—Applications and Pathways to the Clinic,” Nature Reviews Neurology 20, no. 6 (2024): 319–336.

[268] A. J. Schupper, T. Chanenchuk, A. Racanelli, G. Price, and C. G. Hadjipanayis, “Laser Hyperthermia: Past, Present, and Future,” Neuro-Oncology 24, no. S6 (2022): S42–S51.

[269] J. Y. Kang and M. R. Sperling, “Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy for Treatment of Drug-Resistant Epilepsy,” Neurotherapeutics 14, no. 1 (2017): 176–181.

[270] M. Sharma, T. Ball, A. Alhourani, et al., “Inverse National Trends of Laser Interstitial Thermal Therapy and Open Surgical Procedures for Refractory Epilepsy: A Nationwide Inpatient Sample-Based Propensity Score Matching Analysis,” Neurosurgical Focus [Electronic Resource] 48, no. 4 (2020): E11.

[271] H. Waseem, K. E. Osborn, M. R. Schoenberg, et al., “Laser Ablation Therapy: An Alternative Treatment for Medically Resistant Mesial Temporal Lobe Epilepsy After Age 50,” Epilepsy & Behavior 51 (2015): 152–157.

[272] F. R. Ekman, J. Bjellvi, S. Ljunggren, K. Malmgren, and D. Nilsson, “Laser Interstitial Thermal Therapy Versus Open Surgery for Mesial Temporal Lobe Epilepsy: A Systematic Review and Meta-Analysis,” World Neurosurgery 192 (2024): 224–235.e15.

[273] N. Barot, K. Batra, J. Zhang, et al., “Surgical Outcomes Between Temporal, Extratemporal Epilepsies and Hypothalamic Hamartoma: Systematic Review and Meta-Analysis of MRI-Guided Laser Interstitial Thermal Therapy for Drug-Resistant Epilepsy,” Journal of Neurology, Neurosurgery, and Psychiatry 93, no. 2 (2022): 133–143.

[274] P. Bourdillon, M. Cucherat, J. Isnard, et al., “Stereo-Electroencephalography-Guided Radiofrequency Thermocoagulation in Patients With Focal Epilepsy: A Systematic Review and Meta-Analysis,” Epilepsia 59, no. 12 (2018): 2296–2304.

[275] P. S. Pichardo-Rojas, D. Pichardo-Rojas, C. A. Zarate-Duran, et al., “Stereoelectroencephalography-Guided Radiofrequency Thermocoagulation for Drug-Resistant Epilepsy: A Meta-Analysis,” Epilepsia 66 (2025): 3602–3620.

[276] J. de Tisi, G. S. Bell, J. L. Peacock, et al., “The Long-Term Outcome of Adult Epilepsy Surgery, Patterns of Seizure Remission, and Relapse: A Cohort Study,” Lancet 378, no. 9800 (2011): 1388–1395.

[277] H. Kreinter, P. H. Espino, S. Mejia, et al., “Disrupting the Epileptogenic Network With Stereoelectroencephalography-Guided Radiofrequency Thermocoagulation,” Epilepsia 65, no. 7 (2024): e113–e118.

[278] M. D. Smyth, A. K. Vellimana, E. Asano, and S. Sood, “Corpus Callosotomy-Open and Endoscopic Surgical Techniques,” Epilepsia 58, no. S1 (2017): 73–79.

[279] J. A. Gonzalez-Martinez, H. Abou-Al-Shaar, A. N. Mallela, et al., “The Endoscopic Anterior Transmaxillary Temporal Pole Approach for Mesial Temporal Lobe Epilepsies: A Feasibility Study,” Journal of Neurosurgery 138, no. 4 (2023): 992–1001.

[280] H. W. Phillips, T. A. Miller, H. Y. Liu, T. J. Abel, and M. M. McDowell, “Utility of Minimally Invasive Endoscopic Skull Base Approaches for the Treatment of Drug-Resistant Mesial Temporal Lobe Epilepsy: A Review of Current Techniques and Trends,” Journal of Neurosurgery 139, no. 6 (2023): 1604–1612.

[281] M. Rizzi, M. Nichelatti, L. Ferri, et al., “Seizure Outcomes and Safety Profiles of Surgical Options for Epilepsy Associated to Hypothalamic Hamartomas. A Systematic Review and Meta-Analysis,” Epilepsy Research 198 (2023): 107261.

[282] S. Chibbaro, H. Cebula, J. Scholly, et al., “Pure Endoscopic Management of Epileptogenic Hypothalamic Hamartomas,” Neurosurgical Review 40, no. 4 (2017): 647–653.

[283] D. Hansen, S. Shandley, J. Olaya, et al., “A Multi-Center Comparison of Surgical Techniques for Corpus Callosotomy in Pediatric Drug-Resistant Epilepsy,” Epilepsia 65, no. 2 (2024): 422–429.

[284] K. R. Lehner, R. S. D'Amico, and R. Rahme, “Microsurgical Management of Complex Hypothalamic Hamartomas in the Era of Minimally Invasive Therapy: A Case Series and Narrative Review,” World Neurosurgery 160 (2022): e388–e397.

[285] M. Mandel, C. E. Petito, R. Tutihashi, et al., “Smartphone-Assisted Minimally Invasive Neurosurgery,” Journal of Neurosurgery 130, no. 1 (2019): 90–98.

[286] S. J. Lee, P. S. Lee, A. H. Faraji, R. M. Richardson, and V. Kokkinos, “Implantation Accuracy and Operative Variables in Robot-Assisted Stereoelectroencephalography,” Journal of Neurosurgery 139, no. 6 (2023): 1598–1603.

[287] C. Dorfer, G. Minchev, T. Czech, et al., “A Novel Miniature Robotic Device for Frameless Implantation of Depth Electrodes in Refractory Epilepsy,” Journal of Neurosurgery 126, no. 5 (2017): 1622–1628.

[288] J. Gonzalez-Martinez, S. Vadera, J. Mullin, et al., “Robot-Assisted Stereotactic Laser Ablation in Medically Intractable Epilepsy: Operative Technique,” Neurosurgery 10, no. S2 (2014): 167–172.

[289] C. T. Fish, T. Wittayacharoenpong, C. Donaldson, et al., “Evaluation of the Accuracy, Efficiency and Safety of Stereoelectroencephalography With Robotic Assisted Electrode Placement Compared to Traditional Frame Based Stereotaxy,” Journal of Clinical Neuroscience 138 (2025): 111403.

[290] F. N. Vasconcellos, T. Almeida, A. Muller Fiedler, et al., “Robotic-Assisted Stereoelectroencephalography: A Systematic Review and Meta-Analysis of Safety, Outcomes, and Precision in Refractory Epilepsy Patients,” Cureus 15, no. 10 (2023): e47675.

[291] F. C. Gomes, A. L. L. Larcipretti, G. Nager, et al., “Robot-Assisted vs. Manually Guided Stereoelectroencephalography for Refractory Epilepsy: A Systematic Review and Meta-Analysis,” Neurosurgical Review 46, no. 1 (2023): 102.

[292] R. Lu, M. Wang, Y. Zhang, et al., “Safety, Accuracy, and Efficacy of Robot-Assisted Stereo Electroencephalography in Children of Different Ages,” Neurosurgery 95, no. 1 (2024): 137–145.

[293] N. Onorini, G. Mirone, D. Cicala, et al., “Simultaneous Robotic-Assisted Laser Thermal Ablation of Multiple Cortical Tubers for Drug-Resistant Epilepsy in a 17-Year-Old Patient With Tuberous Sclerosis Complex,” World Neurosurgery 192 (2024): 127–129.

[294] T. H. Ung, L. Kahn, L. Hirt, et al., “Using a Robotic-Assisted Approach for Stereotactic Laser Ablation Corpus Callosotomy: A Technical Report,” Stereotactic and Functional Neurosurgery 100, no. 1 (2022): 61–66.

[295] P. Li, Y. Zhou, Q. Zhang, et al., “Frameless Robot-Assisted Stereoelectroencephalography-Guided Radiofrequency: Methodology, Results, Complications and Stereotactic Application Accuracy in Pediatric Hypothalamic Hamartomas,” Frontiers in Neurology 14 (2023): 1259171.

[296] Z. Wu, Q. Zhao, Z. Tian, et al., “Efficacy and Safety of a New Robot-Assisted Stereotactic System for Radiofrequency Thermocoagulation in Patients With Temporal Lobe Epilepsy,” Experimental and Therapeutic Medicine 7, no. 6 (2014): 1728–1732.

[297] M. Abdallat, H. Joswig, A. R. Nazer, et al., “Robot-Assisted Versus Manual Frame-Based Stereoelectroencephalography,” Journal of Neurosurgery 143, no. 3 (2025): 748–754.

[298] B. A. Miller, A. Salehi, D. D. Limbrick, and M. D. Smyth, “Applications of a Robotic Stereotactic Arm for Pediatric Epilepsy and Neurooncology Surgery,” Journal of Neurosurgery: Pediatrics 20, no. 4 (2017): 364–370.

[299] A. N. Mallela, J. Beiriger, Z. C. Gersey, et al., “Targeting the Future: Developing a Training Curriculum for Robotic Assisted Neurosurgery,” World Neurosurgery 167 (2022): e770–e777.

[300] C. He, R. Nguyen, H. Mayer, et al., “Magnetically Actuated Dexterous Tools for Minimally Invasive Operation Inside the Brain,” Science Robotics 10, no. 100 (2025): eadk4249.

[301] C. Brimley and N. Shimony, “Accuracy and Utility of Frameless Stereotactic Placement of Stereoelectroencephalography Electrodes,” World Neurosurgery 180 (2023): e226–e232.

[302] M. Hegde, W. Chiong, and V. R. Rao, “New Ethical and Clinical Challenges in “Closed-Loop” Neuromodulation,” Neurology 96, no. 17 (2021): 799–804.

[303] V. Kokkinos, N. D. Sisterson, T. A. Wozny, and R. M. Richardson, “Association of Closed-Loop Brain Stimulation Neurophysiological Features With Seizure Control Among Patients With Focal Epilepsy,” JAMA Neurology 76, no. 7 (2019): 800–808.

[304] G. Li, Y. Tian, L. Jiang, et al., “A Bimodal Closed-Loop Neuromodulation Implant Integrated With Ultraflexible Probes to Treat Epilepsy,” Biosensors & Bioelectronics 271 (2025): 117071.

[305] R. Zelmann, A. C. Paulk, I. Basu, et al., “CLoSES: A Platform for Closed-Loop Intracranial Stimulation in Humans,” Neuroimage 223 (2020): 117314.

[306] S. Chiang, A. N. Khambhati, T. K. Tcheng, et al., “State-Dependent Effects of Responsive Neurostimulation Depend on Seizure Localization,” Brain 148, no. 2 (2025): 521–532.

[307] R. J. Piper, R. M. Richardson, G. Worrell, et al., “Towards Network-Guided Neuromodulation for Epilepsy,” Brain 145, no. 10 (2022): 3347–3362.

[308] F. Z. Kashoo, R. S. Al-Baradie, M. Alzahrani, et al., “Effect of Transcranial Direct Current Stimulation Augmented With Motor Imagery and Upper-Limb Functional Training for Upper-Limb Stroke Rehabilitation: A Prospective Randomized Controlled Trial,” International Journal of Environmental Research and Public Health 19, no. 22 (2022): 15199.

[309] M. J. Edwards, P. Talelli, and J. C. Rothwell, “Clinical Applications of Transcranial Magnetic Stimulation in Patients With Movement Disorders,” Lancet Neurology 7, no. 9 (2008): 827–840.

[310] N. Torres-Martinez, S. Chabardes, and J. Mitrofanis, “Lights for Epilepsy: Can Photobiomodulation Reduce Seizures and Offer Neuroprotection?,” Neural Regeneration Research 18, no. 7 (2023): 1423–1426.

[311] R. Rao, A. Patel, K. Hanchate, et al., “Advances in Focused Ultrasound for the Treatment of Brain Tumors,” Tomography 9, no. 3 (2023): 1094–1109.

[312] T. Costa, “Focused Ultrasound for Major Depressive Disorder,” Open Access Government January 2023 (2022): 166–167.

[313] E. Lescrauwaet, K. Vonck, M. Sprengers, et al., “Recent Advances in the Use of Focused Ultrasound as a Treatment for Epilepsy,” Frontiers in Neuroscience 16 (2022): 886584.

[314] J. M. Wasielewska and A. R. White, “Focused Ultrasound-Mediated Drug Delivery in Humans—A Path Towards Translation in Neurodegenerative Diseases,” Pharmaceutical Research 39, no. 3 (2022): 427–439.

[315] D. J. Englot, J. D. Rolston, C. W. Wright, K. H. Hassnain, and E. F. Chang, “Rates and Predictors of Seizure Freedom With Vagus Nerve Stimulation for Intractable Epilepsy,” Neurosurgery 79, no. 3 (2016): 345–353.

[316] P. Jain and R. Arya, “Vagus Nerve Stimulation and Seizure Outcomes in Pediatric Refractory Epilepsy: Systematic Review and Meta-Analysis,” Neurology 96, no. 22 (2021): 1041–1051.

[317] D. Revesz, B. Rydenhag, and E. Ben-Menachem, “Complications and Safety of Vagus Nerve Stimulation: 25 Years of Experience at a Single Center,” Journal of Neurosurgery: Pediatrics 18, no. 1 (2016): 97–104.

[318] F. Giordano, A. Zicca, C. Barba, R. Guerrini, and L. Genitori, “Vagus Nerve Stimulation: Surgical Technique of Implantation and Revision and Related Morbidity,” Epilepsia 58, no. S1 (2017): 85–90.

[319] G. Verly, L. B. Oliveira, T. Delfino, et al., “Assessing Short-Term and Long-Term Security and Efficacy of Anterior Nucleus of the Thalamus Deep Brain Stimulation for Treating Drug-Resistant Epilepsy: A Systematic Review and Single-Arm Meta-Analysis,” Epilepsia 65, no. 6 (2024): 1531–1547.

[320] M. C. H. Li and M. J. Cook, “Deep Brain Stimulation for Drug-Resistant Epilepsy,” Epilepsia 59, no. 2 (2018): 273–290.

[321] N. D. Sisterson, V. Kokkinos, A. Urban, N. Li, and R. M. Richardson, “Responsive Neurostimulation of the Thalamus Improves Seizure Control in Idiopathic Generalised Epilepsy: Initial Case Series,” Journal of Neurology, Neurosurgery, and Psychiatry 93, no. 5 (2022): 491–498.

[322] L. Broderick, G. Tuohy, O. Solymos, et al., “Management of Vagus Nerve Stimulation Therapy in the Peri-Operative Period: Guidelines From the Association of Anaesthetists: Guidelines From the Association of Anaesthetists,” Anaesthesia 78, no. 6 (2023): 747–757.

[323] S. Simula, M. Daoud, G. Ruffini, et al., “Transcranial Current Stimulation in Epilepsy: A Systematic Review of the Fundamental and Clinical Aspects,” Frontiers in Neuroscience 16 (2022): 909421.

[324] D. Yang, Q. Wang, C. Xu, et al., “Transcranial Direct Current Stimulation Reduces Seizure Frequency in Patients With Refractory Focal Epilepsy: A Randomized, Double-Blind, Sham-Controlled, and Three-Arm Parallel Multicenter Study,” Brain Stimulation 13, no. 1 (2020): 109–116.

[325] E. Kaufmann, M. Hordt, M. Lauseker, U. Palm, and S. Noachtar, “Acute Effects of Spaced Cathodal Transcranial Direct Current Stimulation in Drug Resistant Focal Epilepsies,” Clinical Neurophysiology 132, no. 7 (2021): 1444–1451.

[326] F. Fregni, P. T. Otachi, A. Do Valle, et al., “A Randomized Clinical Trial of Repetitive Transcranial Magnetic Stimulation in Patients With Refractory Epilepsy,” Annals of Neurology 60, no. 4 (2006): 447–455.

[327] W. H. Theodore, K. Hunter, R. Chen, et al., “Transcranial Magnetic Stimulation for the Treatment of Seizures: A Controlled Study,” Neurology 59, no. 4 (2002): 560–562.

[328] R. Cantello, S. Rossi, C. Varrasi, et al., “Slow Repetitive TMS for Drug-Resistant Epilepsy: Clinical and EEG Findings of a Placebo-Controlled Trial,” Epilepsia 48, no. 2 (2007): 366–374.

[329] D. Walton, D. C. Spencer, S. J. Nevitt, and B. D. Michael, “Transcranial Magnetic Stimulation for the Treatment of Epilepsy,” Cochrane Database of Systematic Reviews (Online) 4, no. 4 (2021): CD011025.

[330] A. E. Saltmarche, M. A. Naeser, K. F. Ho, M. R. Hamblin, and L. Lim, “Significant Improvement in Cognition in Mild to Moderately Severe Dementia Cases Treated With Transcranial Plus Intranasal Photobiomodulation: Case Series Report,” Photomedicine and Laser Surgery 35, no. 8 (2017): 432–441.

[331] C. L. Hamilton, H. El Khoury, D. Hamilton, F. Nicklason, and J. Mitrofanis, ““Buckets”: Early Observations on the Use of Red and Infrared Light Helmets in Parkinson's Disease Patients,” Photobiomodulation, Photomedicine, and Laser Surgery 37, no. 10 (2019): 615–622.

[332] A. Abijo, C. Y. Lee, C. Y. Huang, P. C. Ho, and K. J. Tsai, “The Beneficial Role of Photobiomodulation in Neurodegenerative Diseases,” Biomedicines 11, no. 7 (2023): 1828.

[333] F. D. S. Cardoso, F. Gonzalez-Lima, and N. C. Coimbra, “Mitochondrial Photobiomodulation as a Neurotherapeutic Strategy for Epilepsy,” Frontiers in Neurology 13 (2022): 873496.

[334] T. Kamida, S. Kong, N. Eshima, T. Abe, M. Fujiki, and H. Kobayashi, “Transcranial Direct Current Stimulation Decreases Convulsions and Spatial Memory Deficits Following Pilocarpine-Induced Status Epilepticus in Immature Rats,” Behavioural Brain Research 217, no. 1 (2011): 99–103.

[335] Y. J. Wu, M. E. Chien, C. C. Chiang, Y. Z. Huang, D. M. Durand, and K. S. Hsu, “Delta Oscillation Underlies the Interictal Spike Changes After Repeated Transcranial Direct Current Stimulation in a Rat Model of Chronic Seizures,” Brain Stimulation 14, no. 4 (2021): 771–779.

[336] D. Liebetanz, F. Klinker, D. Hering, et al., “Anticonvulsant Effects of Transcranial Direct-Current Stimulation (tDCS) in the Rat Cortical Ramp Model of Focal Epilepsy,” Epilepsia 47, no. 7 (2006): 1216–1224.

[337] Y. Wang, X. Wang, S. Ke, et al., “Low-Frequency Repetitive Transcranial Magnetic Simulation Prevents Chronic Epileptic Seizure,” Neural Regeneration Research 8, no. 27 (2013): 2566–2572.

[338] A. Fleischmann, S. Hirschmann, O. T. Dolberg, P. N. Dannon, and L. Grunhaus, “Chronic Treatment With Repetitive Transcranial Magnetic Stimulation Inhibits Seizure Induction by Electroconvulsive Shock in Rats,” Biological Psychiatry 45, no. 6 (1999): 759–763.

[339] C. M. Tsai, S. F. Chang, and H. Chang, “Transcranial Photobiomodulation Attenuates Pentylenetetrazole-Induced Status Epilepticus in Peripubertal Rats,” Journal of Biophotonics 13, no. 8 (2020): e202000095.

[340] S. Charbenny and Z. Huang, “Brain Thermal Response to Low Intensity Focused Ultrasound at the Action Potential Level and Neuron Response to Various Stimulus,” Computers in Biology and Medicine 197, no. pt. B (2025): 111094.

[341] Z. Huang, C. C. Charalambous, M. Chen, et al., “Low Intensity Focused Ultrasound Stimulation in Stroke: A Phase I Safety & Feasibility Trial,” Brain Stimulation 18, no. 1 (2025): 179–187.

[342] A. Tsuchiyagaito, R. Kuplicki, M. Misaki, et al., “Reversible Modulation of a Deep White Matter Surgical Target for Depression With Low-Intensity Focused Ultrasound,” Neuropsychopharmacology 51 (2026): 612–621.

[343] C. C. Lee, C. C. Chou, F. J. Hsiao, et al., “Pilot Study of Focused Ultrasound for Drug-Resistant Epilepsy,” Epilepsia 63, no. 1 (2022): 162–175.

[344] K. Abe, T. Yamaguchi, H. Hori, et al., “Magnetic Resonance-Guided Focused Ultrasound for Mesial Temporal Lobe Epilepsy: A Case Report,” BMC Neurology [Electronic Resource] 20, no. 1 (2020): 160.

[345] C. Zhong, K. Yang, N. Wang, et al., “Advancements in Surgical Therapies for Drug-Resistant Epilepsy: A Paradigm Shift Towards Precision Care,” Neurology and Therapy 14, no. 2 (2025): 467–490.

[346] V. Krishna, P. S. Fishman, H. M. Eisenberg, et al., “Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinson's Disease,” New England Journal of Medicine 388, no. 8 (2023): 683–693.

[347] M. G. Kaplitt, V. Krishna, H. M. Eisenberg, et al., “Safety and Efficacy of Staged, Bilateral Focused Ultrasound Thalamotomy in Essential Tremor: An Open-Label Clinical Trial,” JAMA Neurology 81, no. 9 (2024): 939–946.

[348] R. Martinez-Fernandez, S. Paschen, M. Del Alamo, et al., “Focused Ultrasound Therapy for Movement Disorders,” Lancet Neurology 24, no. 8 (2025): 698–712.

[349] A. R. Rezai, M. Ranjan, and P. F. D'Haese, “Noninvasive Hippocampal Blood-Brain Barrier Opening in Alzheimer's Disease With Focused Ultrasound,” Proceedings of the National Academy of Sciences of the United States of America 117, no. 17 (2020): 9180–9182.

[350] H. Hakimova, S. Kim, K. Chu, S. K. Lee, B. Jeong, and D. Jeon, “Ultrasound Stimulation Inhibits Recurrent Seizures and Improves Behavioral Outcome in an Experimental Model of Mesial Temporal Lobe Epilepsy,” Epilepsy & Behavior 49 (2015): 26–32.

[351] P. C. Chu, H. Y. Yu, C. C. Lee, R. Fisher, and H. L. Liu, “Pulsed-Focused Ultrasound Provides Long-Term Suppression of Epileptiform Bursts in the Kainic Acid-Induced Epilepsy Rat Model,” Neurotherapeutics 19, no. 4 (2022): 1368–1380.

[352] T. Choi, M. Koo, J. Joo, T. Kim, Y. M. Shon, and J. Park, “Bidirectional Neuronal Control of Epileptiform Activity by Repetitive Transcranial Focused Ultrasound Stimulations,” Advanced Science 11, no. 2 (2024): e2302404.

[353] Y. Zhang, P. S. Buckmaster, L. Qiu, et al., “Non-Invasive, Neurotoxic Surgery Reduces Seizures in a Rat Model of Temporal Lobe Epilepsy,” Experimental Neurology 343 (2021): 113761.

[354] A. T. Young, N. Cornwell, and M. A. Daniele, “Neuro-Nano Interfaces: Utilizing Nano-Coatings and Nanoparticles to Enable Next-Generation Electrophysiological Recording, Neural Stimulation, and Biochemical Modulation,” Advanced Functional Materials 28, no. 12 (2018): 1700239.

[355] W. Loscher, C. Luna-Tortos, K. Romermann, and M. Fedrowitz, “Do ATP-Binding Cassette Transporters Cause Pharmacoresistance in Epilepsy? Problems and Approaches in Determining Which Antiepileptic Drugs Are Affected,” Current Pharmaceutical Design 17, no. 26 (2011): 2808–2828.

[356] Q. Guan, X. Wang, D. Cao, M. Li, Z. Luo, and X. Mao, “Calcium Phosphate-Based Nanoformulation Selectively Abolishes Phenytoin Resistance in Epileptic Neurons for Ceasing Seizures,” Small 19, no. 29 (2023): e2300395.

[357] J. Lim, S. W. Lee, J. Kim, et al., “Hybrid Graphene Electrode for the Diagnosis and Treatment of Epilepsy in Free-Moving Animal Models,” NPG Asia Materials 15, no. 1 (2023): 7.

[358] D. Yang, Q. Ren, J. Nie, et al., “Black Phosphorus Flake-Enabled Wireless Neuromodulation for Epilepsy Treatment,” Nano Letters 24, no. 4 (2024): 1052–1061.

[359] J. W. Salatino, K. A. Ludwig, T. D. Y. Kozai, and E. K. Purcell, “Glial Responses to Implanted Electrodes in the Brain,” Nature Biomedical Engineering 1, no. 11 (2017): 862–877.

[360] Q. Ren, H. Wu, Y. Zhang, et al., “Nongenetic Precise Neuromodulation and Spatiotemporal Neuroprotection for Epilepsy Therapy via Rationally Designed Multifunctional Nanotransducer,” ACS Nano 18, no. 26 (2024): 16853–16866.

[361] K. M. Woeppel and X. T. Cui, “Nanoparticle and Biomolecule Surface Modification Synergistically Increases Neural Electrode Recording Yield and Minimizes Inflammatory Host Response,” Advanced Healthcare Materials 10, no. 16 (2021): e2002150.

[362] D. Wu, F. Fei, Q. Zhang, et al., “Nanoengineered On-Demand Drug Delivery System Improves Efficacy of Pharmacotherapy for Epilepsy,” Science Advances 8, no. 2 (2022): eabm3381.

[363] A. Lopalco, H. Ali, N. Denora, and E. Rytting, “Oxcarbazepine-Loaded Polymeric Nanoparticles: Development and Permeability Studies Across In Vitro Models of the Blood-Brain Barrier and Human Placental Trophoblast,” International Journal of Nanomedicine 10 (2015): 1985–1996.

[364] X. Song, H. Qian, and Y. Yu, “Nanoparticles Mediated the Diagnosis and Therapy of Glioblastoma: Bypass or Cross the Blood-Brain Barrier,” Small 19, no. 45 (2023): e2302613.

[365] N. C. de Lanerolle, J. H. Kim, R. J. Robbins, and D. D. Spencer, “Hippocampal Interneuron Loss and Plasticity in Human Temporal Lobe Epilepsy,” Brain Research 495, no. 2 (1989): 387–395.

[366] M. Bershteyn, S. Broer, M. Parekh, et al., “Human Pallial MGE-Type GABAergic Interneuron Cell Therapy for Chronic Focal Epilepsy,” Cell Stem Cell 30, no. 10 (2023): 1331–1350.e11.

[367] S. Fadila, B. Beucher, I. G. Dopeso-Reyes, et al., “Viral Vector-Mediated Expression of NaV1.1, After Seizure Onset, Reduces Epilepsy in Mice With Dravet Syndrome,” Journal of Clinical Investigation 133, no. 12 (2023): e159316.

[368] D. Nie, T. Guo, M. Yue, et al., “Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors,” Biomolecules 12, no. 9 (2022): 1239.

[369] S. Cattaneo, B. Bettegazzi, L. Crippa, et al., “Gene Therapy for Epilepsy Targeting Neuropeptide Y and Its Y2 Receptor to Dentate Gyrus Granule Cells,” EMBO Reports 25, no. 10 (2024): 4387–4409.

[370] C. Bernard, “Treating Epilepsy With a Light Potassium Diet,” Science Translational Medicine 4, no. 161 (2012): 161fs40.

[371] D. G. Southwell, C. R. Nicholas, A. I. Basbaum, et al., “Interneurons From Embryonic Development to Cell-Based Therapy,” Science 344, no. 6180 (2014): 1240622.

[372] H. Wichterle, J. M. Garcia-Verdugo, D. G. Herrera, and A. Alvarez-Buylla, “Young Neurons From Medial Ganglionic Eminence Disperse in Adult and Embryonic Brain,” Nature Neuroscience 2, no. 5 (1999): 461–466.

[373] Z. Peng, N. Zhang, W. Wei, et al., “A Reorganized GABAergic Circuit in a Model of Epilepsy: Evidence From Optogenetic Labeling and Stimulation of Somatostatin Interneurons,” Journal of Neuroscience 33, no. 36 (2013): 14392–14405.

[374] X. Maisano, E. Litvina, S. Tagliatela, G. B. Aaron, L. B. Grabel, and J. R. Naegele, “Differentiation and Functional Incorporation of Embryonic Stem Cell-Derived GABAergic Interneurons in the Dentate Gyrus of Mice With Temporal Lobe Epilepsy,” Journal of Neuroscience 32, no. 1 (2012): 46–61.

[375] D. Upadhya, B. Hattiangady, O. W. Castro, et al., “Human Induced Pluripotent Stem Cell-Derived MGE Cell Grafting After Status Epilepticus Attenuates Chronic Epilepsy and Comorbidities via Synaptic Integration,” Proceedings of the National Academy of Sciences of the United States of America 116, no. 1 (2019): 287–296.

[376] V. Volarevic, B. S. Markovic, M. Gazdic, et al., “Ethical and Safety Issues of Stem Cell-Based Therapy,” International Journal of Medical Sciences 15, no. 1 (2018): 36–45.

[377] M. E. Calcagnotto, L. P. Ruiz, M. M. Blanco, et al., “Effect of Neuronal Precursor Cells Derived From Medial Ganglionic Eminence in an Acute Epileptic Seizure Model,” Epilepsia 51, no. S3 (2010): 71–75.

[378] R. F. Hunt, K. M. Girskis, J. L. Rubenstein, A. Alvarez-Buylla, and S. C. Baraban, “GABA Progenitors Grafted Into the Adult Epileptic Brain Control Seizures and Abnormal Behavior,” Nature Neuroscience 16, no. 6 (2013): 692–697.

[379] A. K. Shetty, “Hippocampal Injury-Induced Cognitive and Mood Dysfunction, Altered Neurogenesis, and Epilepsy: Can Early Neural Stem Cell Grafting Intervention Provide Protection?,” Epilepsy & Behavior 38 (2014): 117–124.

[380] K. W. Henderson, J. Gupta, S. Tagliatela, et al., “Long-Term Seizure Suppression and Optogenetic Analyses of Synaptic Connectivity in Epileptic Mice With Hippocampal Grafts of GABAergic Interneurons,” Journal of Neuroscience 34, no. 40 (2014): 13492–13504.

[381] A. J. Cai, K. Gao, F. Zhang, and Y. W. Jiang, “Recent Advances and Current Status of Gene Therapy for Epilepsy,” World Journal of Pediatrics 20, no. 11 (2024): 1115–1137.

[382] D. D. Nedorezova, M. V. Dubovichenko, E. P. Belyaeva, E. D. Grigorieva, A. V. Peresadina, and D. M. Kolpashchikov, “Specificity of Oligonucleotide Gene Therapy (OGT) Agents,” Theranostics 12, no. 16 (2022): 7132–7157.

[383] H. T. Li, P. Viskaitis, E. Bracey, D. Peleg-Raibstein, and D. Burdakov, “Transient Targeting of Hypothalamic Orexin Neurons Alleviates Seizures in a Mouse Model of Epilepsy,” Nature Communications 15, no. 1 (2024): 1249.

[384] Q. A. Nguyen, P. M. Klein, C. Xie, et al., “Acetylcholine Receptor Based Chemogenetics Engineered for Neuronal Inhibition and Seizure Control Assessed in Mice,” Nature Communications 15, no. 1 (2024): 601.

[385] M. C. Walker and D. M. Kullmann, “Optogenetic and Chemogenetic Therapies for Epilepsy,” Neuropharmacology 168 (2020): 107751.

[386] L. Mora-Jimenez, M. Valencia, R. Sanchez-Carpintero, et al., “Transfer of SCN1A to the Brain of Adolescent Mouse Model of Dravet Syndrome Improves Epileptic, Motor, and Behavioral Manifestations,” Molecular Therapy Nucleic Acids 25 (2021): 585–602.

[387] T. Yamagata, M. Raveau, K. Kobayashi, et al., “CRISPR/dCas9-Based Scn1a Gene Activation in Inhibitory Neurons Ameliorates Epileptic and Behavioral Phenotypes of Dravet Syndrome Model Mice,” Neurobiology of Disease 141 (2020): 104954.

[388] M. Li, N. Jancovski, P. Jafar-Nejad, et al., “Antisense Oligonucleotide Therapy Reduces Seizures and Extends Life Span in an SCN2A Gain-of-Function Epilepsy Model,” Journal of Clinical Investigation 131, no. 23 (2021): e152079.

[389] Y. Yuan, L. Lopez-Santiago, N. Denomme, et al., “Antisense Oligonucleotides Restore Excitability, GABA Signalling and Sodium Current Density in a Dravet Syndrome Model,” Brain 147, no. 4 (2024): 1231–1246.

[390] O. V. Aimiuwu, A. M. Fowler, M. Sah, et al., “RNAi-Based Gene Therapy Rescues Developmental and Epileptic Encephalopathy in a Genetic Mouse Model,” Molecular Therapy 28, no. 7 (2020): 1706–1716.

[391] J. A. Depla, M. Sogorb-Gonzalez, L. A. Mulder, et al., “Cerebral Organoids: A Human Model for AAV Capsid Selection and Therapeutic Transgene Efficacy in the Brain,” Molecular Therapy Methods & Clinical Development 18 (2020): 167–175.

[392] A. D'Souza, S. Nozohouri, B. S. Bleier, and M. M. Amiji, “CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood-Brain Barrier and Towards Specific Cellular Targeting,” Pharmaceutical Research 40, no. 1 (2023): 77–105.

[393] T. J. Turner, C. Zourray, S. Schorge, and G. Lignani, “Recent Advances in Gene Therapy for Neurodevelopmental Disorders With Epilepsy,” Journal of Neurochemistry 157, no. 2 (2021): 229–262.

[394] X. Pan, W. Huang, G. Nie, C. Wang, and H. Wang, “Ultrasound-Sensitive Intelligent Nanosystems: A Promising Strategy for the Treatment of Neurological Diseases,” Advanced Materials 36, no. 22 (2024): e2303180.

[395] M. Bershteyn, H. Zhou, L. Fuentealba, et al., “Human Stem Cell-Derived GABAergic Interneuron Development Reveals Early Emergence of Subtype Diversity and Gradual Electrochemical Maturation,” Neuron 113, no. 19 (2025): 3162–3184.e10.

[396] W. Huang, J. Zong, Y. Zhang, et al., “The Role of Circadian Rhythm in Neurological Diseases: A Translational Perspective,” Aging and Disease 15, no. 4 (2024): 1565–1587.

[397] W. Huang, Y. Zhang, Y. Zhou, et al., “Glymphatic Dysfunction in Migraine Mice Model,” Neuroscience 528 (2023): 64–74.

[398] Q. Sun, S. Peng, Q. Xu, et al., “Enhancing Glymphatic Fluid Transport by Pan-Adrenergic Inhibition Suppresses Epileptogenesis in Male Mice,” Nature Communications 15, no. 1 (2024): 9600.

[399] K. Ahn, H. S. Park, S. Choi, et al., “Differentiating Visceral Sensory Ganglion Organoids From Induced Pluripotent Stem Cells,” Nature Methods 21, no. 11 (2024): 2135–2146.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.